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INTRODUCTION 
 “Insulin is not a cure for diabetes; it is a treatment. It enables the 
diabetic to burn sufficient carbohydrates, so that proteins and fats may be 
added to the diet in sufficient quantities to provide energy for the economic 
burdens of life” – Sir Frederick Grant Banting. 
In present life situations, the incidence of diabetes mellitus is growing due 
to increase in population size, senility, modernization, obesity and decrease 
in exercise. The terms insulin-dependent and non-insulin-dependent diabetes 
have become obsolete to appear in the classification because these terms are 
often misused, based on the type of treatment the patient were receiving 
rather than their actual type of diabetes. 
 In the present scenario, type 2 Diabetes Mellitus occurs more 
frequently than other forms of diabetes. More often the predominant feature 
is decrease in the ability of insulin to act on tissues. Subjects with type 2 DM 
usually have insulin resistance and is not frequently diagnosed for many 
years. Hyperglycemia develops slowly over years and so the typical features 
of diabetes mellitus are masked. Their circulating insulin levels may be 
normal or even higher. 
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Estimated No. of people with diabetes in developed & developing 
countries 
 
 
Future percentage increase of diabetic population in different 
countries 
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Burden of disease: 
In 2014, an estimated 422 million people were affected with diabetes 
throughout the world. This estimate was only 108 million in 1980. The 
prevalence throughout the world in 1980 was 4.7%. The prevalence in 2014 
has increased to 8.5%. This increase in prevalence was accounted for an 
increase in life style modifications and obesity. After the year 2000, people 
living with diabetes have risen considerably in developing countries than in 
developed countries1. 
In 2012, Diabetes mellitus caused 1.5 million deaths. Hyperglycemia 
per se by increasing the risks of vascular and other organ morbidities caused 
an additional 2.2 million deaths. So, totally it accounted for 3.7 million 
deaths out of which 43.3% were less than 70 years of age. The death 
percentage due to hyperglycemia in age groups less than 70 years is more in 
developing countries than in developed countries. The laboratory tests that 
are required to distinguish between type 1 and type 2 DM are costly and so, 
separate global estimates of prevalence of two types of diabetes mellitus do 
not exist. Type 2 diabetes mellitus is often a disorder that occurs in adults. 
Now it’s incidence in children is increasing. 
The International Federation for diabetes projects that 438 million 
individuals will be affected by this disorder by the year 2030. Although the 
prevalence of both type 1 and type 2 DM is increasing worldwide, the 
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prevalence of type 2 DM is raising much more rapidly. The cause for this 
rapid increase would be increase in percentage of obese population, decrease 
in physical activity of the population and industrialization. The prevalence 
is alike in men and women above 20 years of age (11.8% and 10.8%, 
respectively). The estimates revealed that in 2030, the greatest number of 
individuals with type 2 diabetes mellitus will be in the age between 45 and 
64. The most of the affected population are from developing countries. 
The epidemiological distribution of diabetes worldwide is projected 
for 2030 in which our country stands first. The projected increase of diabetes 
population in the year 2030 for our country is 150%. 
Diabetes mellitus, showing an iceberg phenomenon cause a 
significant economic burden to the global health-care system. This burden 
can be direct or indirect. Direct medical costs incurred are used for 
preventing and treating diabetes and its related complications. The costs 
incurred included emergency care, out-patient care, in-patient care, supply 
of medicines and consumables. The current IDF estimates project money 
spent on diabetes mellitus is three times more than compared to previous ten 
years. The major contributing factor for the rise in expenditure was purchase 
of patented and branded medicines to treat the patients. Developing countries 
carry a larger proportion of this future global health-care expenditure burden 
than developed countries. The indirect burden is posed on the families of 
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affected individual. There is loss of family income associated with disability 
of the individual or early death of the individual. A research says that 
diabetic population has a chance of spending huge amount of money on 
illnesses when compared to the population without DM. These effects were 
significant in developing countries2. 
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AIM AND OBJECTIVES 
1. To compare HbA1c, Serum magnesium and serum calcium between 
newly diagnosed type 2 DM and type 2DM with duration of more than 
five years. 
2. To compare the nerve conduction parameters of individual nerves 
between newly diagnosed type 2 DM and type 2DM with duration of 
more than five years. 
3. To correlate HbA1c with nerve conduction parameters of individual 
nerves and compare between the two groups. 
4. To correlate HbA1c with serum magnesium and body mass index and 
compare between the two groups. 
5. To correlate serum magnesium with nerve conduction parameters of 
individual nerves in two groups. 
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REVIEW OF LITERATURE 
Introduction to Endocrine Pancreas: 
Pancreas is a composite lobulated organ. It has exocrine and endocrine 
actions. It resembles upper end of a thick walking stick lying sideways with 
handle on right and turned downwards. It develops from two endodermal 
buds namely dorsal and ventral that arise from the part of the gut that later 
becomes the second part of duodenum. The secretory components are 
derived from the proliferation of the primitive ducts. The islets of 
Langerhans are derived from the primitive duct system3. More than one 
million islets are found in human pancreas.  An islet consists of polygonal 
or round cells arranged in cords and separated by blood capillaries. There is 
a slight abundancy of islets in the tail of pancreas. Immunocytochemical 
methods identify four types of cells –A, B, D and F. In humans A-cells have 
regular granules with a dense core surrounded by a clear region bounded by 
membrane. They contain immune reactive glucagon. A-cells are identical 
with those found in the gastric antrum. B-cells have irregular granules that 
are rhomboid shaped with a core formed of irregular crystals of insulin in 
complex with zinc. Both endocrine cells and blood vessels of islets are 
innervated by autonomic nerve fibres. A-cells are predominant in periphery. 
B-cells are usually concentrated in central region. The distribution of D and 
F cells are variable. D-cells contain granules of low density and 
immunoflurosence studies suggest the presence of gastrin. A-cells and B-
cells are separated only by peri-capillary spaces, so glucagon could easily be 
transported to act directly on B-cells and thus promote the secretion of 
insulin4.  
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Islet of Langerhans 
 
PATH TO INSULIN 
This story of earliest identification of diabetes mellitus and the way to 
the discovery of the remedy is filled with triumphs, defeats and serendipity.  
 The best earliest evidence occurred in 1550 B.C. when a symptom of 
diabetes mellitus was recorded in Ebers papyrus. Then the description 
of polyuria to Imhotep, a man of medicine, architecture and magic, 
who was a high priest and minister to the Pharoah Zosser in 3000 B.C.  
was documented. 
 Galen and Arateus, the two Greek physicians described the disease 
further. Arateus in his work “Acute and Chronic disease” coined the 
term “Diabetes” meaning “Siphon” to explain “the liquefaction of the 
flesh and bones into urine”.  
 Susruta, an ancient Indian surgeon in 400 B.C. has described the 
diabetic syndrome as “Honeyed urine”. 
 In 1674, Thomas Willis, a physician, an anatomist and professor of 
natural philosophy in Oxford university identified that individuals 
with diabetes  produced sweet urine. He discovered that by “Tasting”.  
 In 1776, Mathew Dobson from Manchester demonstrated that the 
persons with diabetes mellitus actually excrete sugar in urine.  
 In 1815, French chemist Cherreul discovered that the sugar in diabetic 
urine was glucose.  
 In 1850, Claude Bernard described the ‘internal secretion’ of glucose 
into blood from its storage form ‘glycogen’ in the liver.  
 The pancreatic islets were discovered in 1868 by Paul Langerhans 
when he was a medical student in Berlin.  
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 Minkowski and Von Mering in 1889 demonstrated that  
pancreatectomy  from dogs caused increase in plasma glucose, 
increase in urination, increase in thirst, weight loss and finally death, 
a syndrome closely resembling type 1 DM. Following this lead, a 
group of investigators in the Department of Physiology at the 
University of Toronto prepared extracts of pancreas and tested the 
ability of these extracts to lower plasma glucose in pancreatectomized 
dogs. Despite months of failures, these investigators persisted in their 
belief that such extracts could be beneficial. 
 
 It was in 1921, when Sir Frederick Grant Banting-a young 
surgeon;John Macleod-Professor of physiology;Charles Herbert Best-
a fourth year medical graduate as well as an assistant to John Macleod 
and J.B. Collip a skilled chemist commenced their work in the 
laboratory of Prof. Mcleod. They did their experiments on dogs and 
isolated a substance, ‘Isletin’ now called insulin which found to 
decrease blood glucose level. Nobel Prize was awarded in October 
1923, 18 months after their discovery. That event was a gripping tale 
of success, disappointment and conflict. Banting and Macleod were 
honoured, but still both shared their prizes with the counterparts. The 
first patient to be treated with the extract of the substance was Leonard 
Thompson 14 year old boy with metabolic acidosis5. 
 In 1926, crystalline insulin was prepared by Abel. Sanger and 
coworkers, in 1955 delineated the structure of insulin. Proinsulin was 
discovered in 1967.  
 First pancreas transplant was conducted in 1967. Lacy and coworkers 
started islet cell transplants in the year 19896.      
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Synthesis of Insulin: 
In humans, the gene for insulin is located on the short arm of 
chromosome 11. Insulin as any other protein is produced in the rough 
endoplasmic reticulum of beta cells of pancreas. It is then taken to the Golgi 
apparatus for packaging and these packed substances move to the beta cell 
membrane and is exocytosed.  Insulin is produced as part of a larger pre-
prohormone which after cleavage of a peptide forms pro insulin. The 
connecting peptide (C peptide), connects A and B chains and facilitates the 
folding after which it is detached in the granules before secretion. The insulin 
then enters the neighboring fenestrated capillary endothelium to reach the 
bloodstream. Insulin constitutes about 90–97% of the products released from 
the β cells. The level of C-peptide which is secreted in equimolar 
concentrations of insulin is determined by radio immunoassay. The C-
peptide level in blood serves as a marker of β cell function in patients 
receiving parenteral insulin. The half-life of insulin in the circulation in 
humans is 5 minutes. Insulin binds to its receptors found on many different 
cells in the body. It also binds to cells in which they do not increase glucose 
uptake7. 
Insulin Receptor: 
The gene for receptor of insulin is located on chromosome 19. It has 
a molecular weight of approximately 340,000. It is a tetramer made up of 2 
alpha and 2 beta glycoprotein subunits synthesized by a single mRNA and  
12 
 
 
Synthesis and processing of insulin molecule 
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Insulin, IGF-1 and IGF-II receptors 
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then separated by proteases. They are bonded to each other by disulfide 
bonds. The alpha subunits bind to insulin molecules and are present extra-
cellularly. The β subunits span the cell membrane. The intracellular portions 
of the β subunits have tyrosine kinase activity. Both subunits are 
glycosylated. When insulin binds to the receptor, the tyrosine kinase activity 
of the β subunits, produces autophosphorylation of the β subunits. 
Mice knocked out of insulin receptor gene show features of growth 
stunting in fetal period. They have abnormalities of skin, nervous system, 
and die at birth due to respiratory insufficiency. The protein anabolic effects 
of insulin are mediated through PI3K. This enzyme pathway is involved in 
the growth of nerve cells in the visual system. The insulin receptor is very 
similar to IGF I receptor but different from IGF-II receptor. The growth 
factor receptors also have tyrosine kinases but their amino acid composition 
is different. When insulin binds to its receptors, they form an aggregation 
and then these patches are taken into the cell by receptor mediated 
endocytosis. The insulin–receptor complexes enter lysosomes, where the 
receptors are broken down or recycled. The half-life of the insulin receptor 
is around 7 hours8, 9. 
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Actions of Insulin10,11: 
TIME OF ONSET ACTION 
 
 
RAPID-in seconds 
Increased transport of glucose into 
insulin sensitive cells 
Increase in transport of amino acids 
into  cells sensitive for insulin 
Increased transport of K+ into insulin 
sensitive cells 
 
 
 
INTERMEDIATE -in minutes 
Protein synthesis stimulation 
Protein degradation inhibition 
Activation of enzymes of glycolysis 
and glycogen synthetase enzyme 
Inhibition of enzymes such as 
phosphorylase and few 
gluconeogenic enzymes 
DELAYED-in hours mRNAs for lipogenesis increases 
 
Effect of Insulin in Various Tissues: 
General: 
 Growth of all cells is increased 
Adipose tissue: 
 Increases entry of glucose into cells 
 Increases synthesis of fatty acids 
 Increases the production of glycerol phosphate 
 Activates lipoprotein lipase 
 Increases potassium uptake 
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 Increases the deposition of triglycerides 
Muscle: 
 Increases synthesis of glycogen 
 Increases entry of glucose 
 Amino acid uptake is increased 
 Ribosomal protein synthesis is increased 
 Protein breakdown is decreased 
 Decreased release of gluconeogenic amino acids 
 Increased ketone uptake 
 Potassium uptake is increased 
Liver: 
 Ketogenesis is decreased 
 Protein synthesis is increased 
 Lipid synthesis is increased 
 Glucose output is decreased due to decreased gluconeogenesis 
 Glycolysis and glycogen synthesis are increased12 
Regulation of Insulin Secretion: 
Insulin secretion is chiefly regulated by blood glucose levels through 
negative feedback. On entry into the cell glucose is metabolized to ATP. 
This accumulation of ATP causes closure of potassium channels and result 
in cell depolarization. This depolarization cause Ca2+ influx activates kinases 
and thus resulting in insulin secretion. 
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Glucose mediated insulin secretion 
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      Glucose transporters and Glucose utilization in various tissues 
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Amino acids, especially arginine, leucine and lysine increases insulin 
secretion. The secretion of insulin is increased after a protein meal. Arginine 
is a precursor of nitric oxide and so, nitric oxide itself stimulates insulin 
secretion. Fatty acids and ketone bodies increase insulin secretion when their 
blood levels are high. 
Influence of gastrointestinal hormones- Gastric inhibitory peptide, 
gastrin, secretin and cholecystokinin-pancreozymin increases insulin 
secretion. The physiological “gut factor” gastric inhibitory peptide is found 
to be the cause of increased insulin secretion following an orally 
administered glucose load than a same dose administered intravenously. 
Acetylcholine increases insulin secretion whereas it is blocked by atropine. 
β-adrenergic blockers and -adrenergic agonists inhibit insulin secretion 
whereas β- adrenergic agonists increase insulin secretion13. 
Glucose Metabolism: 
Glucose stimulates insulin secretion when blood glucose 
concentration is over 70 mg/dl. Glucose is transported into beta cells by 
facilitated diffusion through a transporter protein, called GLUT. The rate-
limiting step in glycolysis is the phosphorylation of glucose by glucokinase 
that controls glucose-regulated insulin secretion. This metabolism of glucose 
through glycolysis generates ATP, which accumulate and inhibit the activity 
of an ATP-sensitive K+ channel. This ATP-sensitive K+ channel consists of 
a binding protein site for certain oral hypoglycemic, and the other protein 
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site is an inwardly rectifying K+ channel protein. Inhibition of this potassium 
channel induces beta cell membrane depolarization, which opens voltage-
dependent calcium channels. This calcium released by the above process 
cause insulin secretion from the stored granules. Insulin is secreted in a 
pulsatile pattern, with small secretory bursts occurring every 10 minutes. 
Incretins are produced in the neuro-endocrine cells of the gastrointestinal 
tract. These are produced following food ingestion and they amplify glucose-
stimulated insulin secretion and suppress glucagon secretion. Glucagon-like 
peptide-1 is the most potent incretin. It is released from ‘L’ cells in the small 
intestine and it stimulates secretion of insulin only when the blood glucose 
is above the fasting level14. 
Glucose homeostasis: 
Homeostasis is maintenance of constancy. Glucose is maintained in a 
constant concentration when there is a balance between production of 
glucose and its peripheral uptake and utilization. Neural signals, metabolic 
inputs, and various hormones result in an integrated control of glucose 
supply and utilization of glucose. Among all, the prime regulator is insulin. 
In the fasting state, low insulin levels promotes gluconeogenesis and 
glycogenolysis in liver and reduce glucose uptake in insulin-sensitive tissues 
like skeletal muscle and adipose tissue. This promotes the mobilization of 
stored precursors such as amino acids and free fatty acids. Glucagon is  
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Feedback loops of insulin secretion 
  
22 
 
another hormone produced by alpha cells of pancreas. It stimulates 
gluconeogenesis and glycogenolysis when insulin is low.  Postprandially, 
the glucose load cause a rise in insulin and fall in glucagon, leading to a 
reversal of these processes. Insulin is an anabolic hormone. It promotes the 
storage of carbohydrate and fat and helps in protein synthesis. The majority 
of postprandial glucose is utilized by skeletal muscle, by a mechanism called 
insulin-stimulated glucose uptake. Other tissues, most notably the brain, 
utilize glucose in an insulin-independent fashion15, 16. 
NORMAL NERVE METABOLISM AND PHYSIOLOGY: 
Mammalian tissues, under physiological conditions maintain a 
dynamic balance between the rate of production and utilization of ATP. 
Whenever there is a restriction of ATP production, the cells use their 
phosphocreatinine stores for ATP production, decrease the energy requiring 
biological activities or increase glycolysis for ATP production. Under 
physiological conditions, glucose is the major substrate for energy 
production in the peripheral nerve endoneurium. Insulin does not regulate 
the metabolism of these tissues. Cells cannot survive for prolonged periods 
of restricted ATP production, particularly if it is due to ischemia. In ischemia 
there is reduction of not only oxygen but also provision of adequate glucose 
required for glycolysis. This results in rapid accumulation of lactate and 
development of acidosis. 
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PHYSIOLOGY OF NERVE CONDUCTION: 
Historical Aspects: 
 Invention of cathode ray oscilloscope in 1897 by Braun was the 
breakthrough in the study of action potentials.  
 In 1903 string galvanometer was found out by Einthoven. Muscle 
action potential instead of the muscle twitch was recorded in the 
measurement of conduction velocity in motor nerves by Piper in year 
1909 and Munnich in 1916.  
 By stimulating tibial nerve Hoffmann demonstrated the monosynaptic 
reflex in soleus muscle. It was named as H reflex in 1918.   
 In 1922, Joseph Erlanger and Herbert Spencer Gasser, a student of the 
former found out that difference in conduction velocity of  in nerve 
fibres is directly proportional to diameter of nerve fibres. Based on 
this finding they grouped nerve fibres into three different groups. The 
large nerve fibres were grouped as type A-fiber with maximum 
velocity and smaller fibres as type C with minimum velocity. In 1944 
they received Nobel Prize for the same17.  
 By stimulating the motor nerves Harvey and Masland observed the 
decremental response in myasthenia gravis in 1941. In 1957 Eaton and 
Lambert used the same procedure in various neuromuscular disorders 
including myasthenic syndrome. 
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 Alan Lloyd Hodgkin and Andrew F. Huxley did study on Squid and 
cattle fish having giant axons because it is easy to introduce many 
electrodes and measure the resting membrane and action potential. 
They demonstrated the membrane permeability to sodium and 
potassium in various phases of action potential and also refractoriness 
of nerve fibres for about 1 ms.  They were the pioneers in devising 
voltage clamp method. They also found out the different bands in 
skeletal muscle fiber and elaborated  the “sliding filament theory” of 
muscle contraction. In 1963, Hodgkin, Huxley and John Eccles were 
awarded the Nobel Prize.  
 Changes in the nerve conduction parameters in peripheral 
neuropathies were studied by Harvey and Kutfer by doing nerve 
conduction study. The slowing effect of nerve impulse propagation in 
ischemia was the observation by Kugelberg in 1944 and Cobb and 
Marshall in 195418. Conduction velocity was calculated for the first 
time by Hodes, Laravee and German in 1948.They did it so by 
stimulating a nerve at its various levels. The principle of photographic 
superimposition in the calculation of nerve conduction velocity in 
sensory nerve was used by Dawson and Scott in 194919. Dawson by 
devising digital nerve stimulation technique in 1956 differentiated the 
sensory potential from antidromic impulse in motor nerve. Use of 
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nerve conduction studies in the differentiation of demyelinating 
disease and axonal neuropathy was adopted by Lambert and Kaeser.  
 From the year 1960, sensory nerve conduction study was made as an 
integral part of electro diagnostic study in neurophysiology. 
 
MOTOR CONDUCTION STUDY: 
In motor conduction study, nerve is stimulated over two points with 
supra threshold strength. Minimum distance of 10 cms is required between 
two points of stimulation. This distance is changed to shorter segments in 
the evaluation of entrapment neuropathies like carpal tunnel syndrome. The 
latency in milliseconds is taken from the point of stimulus-artifact to the first 
negative deflection. Onset latency includes residual latency also. Residual 
latency is constituted by neuromuscular transmission time and propagation 
time along the muscle membrane. For amplitude measurements, either 
baseline to the first negative peak or from a peak to the next peak is used. 
The unit of amplitude is the millivolt. Duration is measured between onset 
of negative peak or onset of positive peak or onset to final return to baseline. 
The conduction velocity in meter per second is calculated by dividing the 
distance between two points and the difference between the two latencies. 
Elimination of residual latency is thus achieved by measuring the difference 
between the two latencies. Latency denotes the conduction of the impulse in 
fast conducting motor fibres and number of intact nerve fiber is indicated by 
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the amplitude. There is a correlation between the density of small fibres and 
the duration of the amplitude20. 
 
F Wave: 
When motor neurons are stimulated antidromically, it results in 
conduction of the impulse to and from spinal cord. It is done by stimulus 
with supra maximal strength. The cathode is placed proximally and anode 
distally. 
SENSORY CONDUCTION STUDY: 
There are two types of sensory conduction measurements. In 
antidromic conduction study, action potential is recorded over the distal 
point on the nerve while the stimulation is applied on the proximal point of 
the nerve. Reverse process is followed in orthodromic conduction. Distal 
portion is usually a digital nerve. The surface and ring stimulating electrodes 
are used for antidromic and orthodromic conduction measurement 
respectively. Needle electrodes are used in difficult situations. 
SNAP is a triphasic waveform in orthodromic conduction. Triphasic 
response is due to initial positive peak. This initial positive peak is absent in 
antidromic conduction studies. Sensory latency is a measurement between 
the stimulus-artifact to the first positive peak or negative peak. The 
amplitude of SNAP is either measured between the base line to negative 
peak or between negative and positive peaks. Measurement between initial 
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positive peak and the intersection of descending phase to base line gives a 
measure of duration of SNAP. It can also be measured between the initial 
positive peaks to final return to baseline or between initial positive peaks to 
subsequent positive peak. As no residual latency is present in sensory 
conduction study, nerve conduction velocity can be determined by 
stimulating the nerve at only one point. Distance between stimulating and 
recording site divided by latency gives rise to velocity of sensory nerve 
fibres. The duration signifies the number of fibres of slow conducting type 
and the amplitude indicates the density of nerve fibres21. 
FACTORS INFLUENCING CONDUCTION PARAMETERS: 
These factors are due to physiological variation or the technical 
factors involved in conduction study. Age, limb under study and body 
temperature are the physiological variables affecting the conduction studies 
.Technical factors influencing are the stimulating and recording systems of 
the equipments used and faulty stimulation of the nerve not under study and 
abnormalities of the nerves. 
(i) AGE: 
Myelination is not complete at birth. It takes two years for completion of 
myelination after birth. So in a new born child or infant, the conduction 
velocity is low as compared to adults. It reaches the normal value of the adult 
around three to five years of age. Even though degenerative changes in 
nerves take place in old age, the conduction velocity is not decreased more 
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than 10 meters per second even at eighty years of age. There is a positive 
correlation between latency of F wave and advancing age22. 
 
(ii) LIMB UNDER STUDY: 
Nerves of the upper limbs conduct the nerve impulse faster than the 
nerves of the lower limb. It applies to both motor and sensory nerves. This 
is due to the fact that length of the upper limb nerves is shorter than that of 
lower limb nerves. Temperature of the hands is more than the temperature 
of feet. Proximal nerve in a limb conducts impulse faster than the distal 
nerves. 
(iii) TEMPERATURE: 
The change in the temperature affects the nerve conduction parameter 
in both motor and sensory conduction studies. If the temperature decreases 
by one degree Celsius, there is an increase in latency of 0.3 meter per second. 
Change in the temperature alters the activity of sodium channels. When the 
temperature is changed from 29 degree celsius to 38 degree Celsius, the 
conduction velocity is increased by 5 % per degree celsius. This error can be 
avoided by performing the study in room temperature 21 to 23 celsius. If 
measured limb temperature is below the 34 degree Celsius the warming of 
limb is to be carried out by immersing the limb in hot water or by using 
infrared lamps23. 
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(iv) STIMULATING SYSTEMS: 
Failure in stimulating system leads to sub maximal stimulation of 
nerves. Due to the failure, the applied stimulus fails to travel up to the target 
part. Both these factors bring about no response or reduced response in the 
study. The failure may be due to the incorrect placement of stimulators. 
Sweat may influence the conduction. In order to avoid the failure of the 
system, the stimulating electrodes should be placed closure to the nerve and 
with the adequate firm pressure. If patient is obese or has edema needle 
electrodes can be used. 
(v) RECORDING SYSTEM: 
Incorrect placement of active or reference electrode alters the wave 
pattern. For example, if active electrode is placed in incorrect position, an 
initial positive wave is produced instead of initial negative wave. This can 
also occur due to the abnormalities of nerve supply or unintentional 
stimulation of nearby nerves. Hence an investigator should know the 
anatomical variations of the nerve. 
(vi) INADVERENTLY STIMULATING THE NERVES NOT 
STUDIED: 
The applied stimulus current sometime stimulates the nearby nerve or 
nerve roots which are not involved under study. This leads to false result in 
latency variables. 
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(vii) ABNORMALITIES IN THE INNERVATION PATTERN: 
Abnormal connection between the nerve produce changes in the 
amplitude. These abnormal connections may be in the form of connection 
between the median nerve and ulnar nerve (Martin Gruber anastomosis). 
This abnormal connection leads to abnormal nerve supply. So before starting 
nerve conduction studies, all the above factors changing the result should be 
kept in mind to diagnose the nerve conduction abnormality24. 
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PATHOPHYSIOLOGY OF DIABETES MELLITUS 
Definition: 
 Diabetes mellitus is a heterogeneous group of metabolic disorder 
characterized by elevated blood glucose and associated with disturbances in 
carbohydrate, fat and protein metabolism resulting from defect in secretion 
of insulin, action of insulin action or both. 
Criteria for Diagnosing Diabetes Mellitus: 
 Symptoms of DM plus blood glucose taken randomly> 200 mg/dl  
 Blood glucose taken in fasting > 126 mg/dl 
 2 hour blood glucose > 200 mg/dl after an oral glucose tolerance test25 
Any one of the above criteria can be used for diagnosing DM. 
Genetics of type 2 DM: 
 A powerful approach to the identification of genetic variants that 
predispose to type 2 DM is still on a hunt while a lot have already been 
explored. Single nucleotide polymorphism has created a path in identifying 
the possible variations involved in its genetics. Genetic studies were based 
on two strategies. First is to focus on the functional candidate genes and 
other on the positional candidate genes. 
 Studies of functional candidate genes involved genes responsible for 
the actions of insulin. Mutation in the insulin receptor gene, though 
uncommon have been implicated in severe form of insulin resistance in type 
2 DM. One of the best characterized molecules in the intracellular insulin 
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action cascade is insulin receptor substrate (IRS-1). This is a cytosolic 
protein that is tyrosine phosphorylated by the insulin receptor. A total of nine 
substitutions have been identified till now out of which the most prevalent is 
the glycine-to-arginine substitution. PI-3 kinase is the major protein that is 
bound and activated by phosphorylated IRS. A reduction in the insulin 
response of this enzymatic activity has been reported in muscle and adipose 
tissue from insulin-resistant subjects with type 2 DM. While insulin has 
pleiotropic effects on cellular functions, the actions that have been 
specifically shown to be impaired in type 2 DM are those related to glucose 
uptake and incorporation into glycogen. GLUT-4 gene and glycogen 
synthase gene have been extensively studied. Multiple defects in the activity 
of this enzyme, glycogen synthase in the skeletal muscle of patients with 
type 2 DM have been positively correlated. Genes involved in GLUT-2 and 
the enzyme glucokinase play a central role in sensing of glucose. 
Glucokinase mutations cause maturity onset diabetes of young. Adenine 
nucleotide-sensitive potassium channels play a vital role in coupling glucose 
metabolism to insulin release. The genes encoding for the subunits of this 
channel are called KCNJ11 & SUR1.  
Diabetes mellitus was previously classified on the basis of the age of 
diagnosis or based on therapy but now it is classified based on the 
etiopathogenetic process that leads to persistent elevation in blood glucose. 
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The two broad types of DM are designated type 1 and type 2. Both types of 
diabetes have a phase of abnormal glucose homeostasis as the disorder 
progress. Type 1 DM is the result of complete or near-total deficiency of 
insulin.  
Type 2 DM is a group of disorder characterized by variable degrees 
of insulin resistance, impaired insulin secretion, and increased glucose 
production. Type 2 DM is preceded by a period of abnormal glucose 
homeostasis classified as impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT). Visceral or central obesity is very common in type 2 DM. 
In the early stages of the disorder, pancreatic beta cells compensate by 
increasing insulin output and so glucose tolerance remains near-normal, 
despite insulin resistance.  
As insulin resistance and compensatory hyperinsulinemia advances, 
endocrine pancreatic cells are unable to sustain the hyperinsulinemic state. 
Impaired glucose tolerance, followed by elevations in postprandial blood 
glucose develops. A further decline in insulin secretion and an increase in 
hepatic glucose production lead to overt diabetes with fasting 
hyperglycemia. At last, pancreatic beta cell failure occurs. 
Insulin secretion and insulin sensitivity are inter-related. When an 
individual becomes more insulin resistant or when insulin sensitivity 
decreases (curve moves from point A to point B), insulin secretion increases.  
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Relationship of insulin sensitivity and secretion in IGT and Type 2 DM 
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A failure to compensate by increasing the insulin secretion occurs and results 
in IGT (point C) and finally to type 2 DM (point D). 
Insulin secretion and sensitivity are inter-related. In type 2 DM, 
insulin secretion initially increases in response to insulin resistance to 
maintain normal glucose levels. Initially, secretion of insulin is affected 
mildly and it particularly involves glucose-stimulated insulin secretion. The 
response to other substances, such as arginine, is preserved. The 
abnormalities in proinsulin processing are noted by increased secretion of 
proinsulin in type 2 DM. The reasons for the decline in insulin secretory 
capacity in type 2 DM is still vague. Pancreatic beta cell mass is decreased 
by 40% in individuals with prolonged type 2 DM. Islet amyloid polypeptide 
(IAPP) or amylin is secreted by the beta cell along with insulin and this forms 
the amyloid deposit that are found in the islets of individuals with type 2 DM 
for longer duration. 
In type 2 DM, due to insulin resistance in the hepatocytes, 
hyperinsulinemia fails to suppress gluconeogenesis, thus resulting in 
elevated fasting blood glucose and decreased glycogen storage by the liver 
in the fed state. As a result of insulin resistance in adipose tissue, fat break 
down and free fatty acid flux from fat cells are increased, leading to 
increased lipid synthesis in hepatocytes. This storage of fat in the liver lead 
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to nonalcoholic fatty liver disease and abnormal liver function tests, 
responsible for the dyslipidemia found in type 2 DM 26. 
Type 2 DM - A Disease of Fat Metabolism 
In type 2 DM, the prime abnormality is an accelerated fat breakdown 
and decreased synthesis of fatty acids and triglycerides leading on to 
increased ketone body production. So, it has been considered “more a 
disease of lipid than of carbohydrate metabolism.” In a normal individual 
after a carbohydrate meal 50% of ingested glucose is burnt to carbon dioxide 
and water through glycolysis, 30–40% is converted to fat and 5% is stored 
as glycogen for future use. In type 2 DM, less than 5% of the ingested 
glucose is converted into fat, in spite of a decrease in the amount burnt to 
CO2 and H2O. But there is no change in the amount converted to glycogen. 
So, blood glucose level increases and the extra glucose is passed in urine. In 
diabetes, there occurs an intracellular deficiency of glucose and so 
conversion of carbohydrates to lipids in the depots is decreased. Insulin 
inhibits the hormone-sensitive lipase in adipose tissue. So, in the absence of 
this hormone the plasma level of free fatty acids is doubled. Free fatty acids 
are mobilized to circulation pool by glucagon and it parallels the plasma 
glucose level in diabetes.  
Free fatty acid levels in blood are a better indicator of the severity of 
the diabetic state. In the liver and other tissues, the fatty acids are catabolized 
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to acetyl-CoA. Some of the acetyl-CoA is burnt along with amino acids to 
yield CO2 and H2O in the Citric Acid Cycle. However, the supply exceeds 
the capacity of the tissues to catabolize the acetyl-CoA. Due to (a) excess 
catabolism of fatty acids, (b) increased gluconeogenesis and (c) marked 
outpouring of glucose into circulation, conversion of acetyl-CoA to malonyl-
CoA and thence to fatty acids is markedly impaired. This happens due to a 
deficiency of acetyl-CoA carboxylase, the enzyme that catalyzes the above 
conversion. The excess acetyl-CoA is converted to ketone bodies. In 
uncontrolled diabetes, the plasma concentration of triglycerides, 
chylomicrons and free fatty acids are increased, and so the plasma is often 
lipemic. The rise in these substances is mainly due to decreased activity of 
lipoprotein lipase which helps in the removal of triglycerides into fat depots.  
 
CALCIUM AND TYPE 2 DIABETES MELLITUS 
Ca2+ signaling in the β-cell: Calcium is a very essential second messenger 
in cells, involved in a various cellular processes including cell growth, 
regulation of genes, cell proliferation, metabolism, exocytosis, and 
programmed cell death. Calcium levels should be strictly regulated as high 
levels are toxic to cells. Cytosolic baseline levels of calcium are typically 
10,000 times lower than the extracellular environment. The endoplasmic 
reticulum serves as a major intracellular calcium store. It stores micro molar 
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amounts of the molecule. Calcium is involved in signaling whether initiated 
extrinsically or intrinsically. These calcium signals can originate from 
channels on the endoplasmic reticulum, the inositol phosphate-3 receptor, 
ryanodine receptor, a ligand-gated channel or from the various other 
channels and pumps on the plasma membrane, or from other organelles such 
as the golgi apparatus and mitochondria. There are various channels and 
pumps that buffer calcium, to turn signals off and return the cytoplasmic 
calcium to normal levels, including sarcoplasmic endoplasmic reticulum 
calcium ATPase (SERCA) pump. Altogether, multitude mechanisms 
operate synchronously as a toolkit creating a complex code controlling vast 
array of cellular processes27. Calcium signaling that occur in pancreatic β-
cells was studied in detail. The intracellular calcium channels and membrane 
calcium channels create cytosolic calcium oscillations which create an 
oscillatory insulin secretion in glucose-stimulated β-cells. The cascade of 
events leading to glucose-stimulated calcium signaling in β-cells starts when 
glucose is internalized by the transporter protein. The glucose that has 
entered the beta cell undergoes anaerobic glycolysis and thus increases 
ATP/ADP ratio. The increased ATP inhibits K+ ATPase channel resulting in 
depolarization and activation of voltage-dependant calcium channels present 
on plasma membrane.  The increase in calcium concentration just beneath 
the cell membrane regulates docking and fusion of secretory granules, 
resulting in insulin secretion. This secretion is pulsatile in fashion, and it 
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creates oscillations in plasma insulin levels that are crucial for insulin action 
on its target tissues28. 
MAGNESIUM AND TYPE 2 DIABETES MELLITUS: 
A 70 kg man contains 35 grams of magnesium. About 55-60% of 
magnesium is combined with calcium and phosphorus in the bones. 20-25% 
is located in soft tissue and 1% is present in body fluids. The recommended 
dietary allowance for magnesium is 400-420 mgms in males and 310-320 
mgms in females. Magnesium is widely distributed in foods, especially plant 
foods, because it is part of the chlorophyll molecules. Green vegetables, nuts, 
legumes, seafood, chocolate, whole grain cereals, coffee, tea and cocoa are 
rich in magnesium. Magnesium is absorbed throughout the small intestine, 
mostly in the distal jejunum and ileum and also absorbed in the colon if 
disease has impaired the small intestine absorption. When a person is taking 
a normal diet 40-60% of magnesium is absorbed, but a smaller % is absorbed 
at high intakes and a larger % at low intakes. Serum magnesium 
concentration in the blood is maintained within a narrow range by the small 
intestine and kidney. Small intestine and kidney increase their magnesium 
absorption whenever necessary. If even greater amounts are required, the 
bones can release some magnesium into the extra cellular compartment. 
Excess magnesium is eliminated by the kidneys. Such excretion can be 
increased by protein, alcohol, and caffeine consumption29.  
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Calcium and phosphorus inhibit magnesium absorption. High zinc 
intake may be a health concern for individuals consuming less magnesium. 
In addition, calcium and magnesium compete with each other for 
reabsorption in kidneys. Inadequate dietary intake usually does not cause 
deficiency rather it is the increased excretion results in magnesium 
deficiency30. 
Magnesium participates in greater than 300 essential metabolic 
reactions. Magnesium is necessary for the transmission of nerve impulses 
and the relaxation of skeletal muscles after contraction. Magnesium activates 
the enzymes that add the 3rd phosphate group to ADP to form ATP. It 
activates enzymes for the metabolism of carbohydrates, fats, and proteins, 
including protein synthesis. It also helps in the release of energy from muscle 
glycogen. Magnesium acts a cofactor in calcium utilization for bone 
formation and also helps to hold calcium in tooth enamel, thus preventing 
tooth decay31. 
Magnesium deficiency is a common occurrence, especially in older 
people with decreased oral intake, people with chronic alcoholism and those 
who use diuretics. In a study of emergency department clients on whose 
serum magnesium was determined, 31% had low magnesium and this was 
statistically associated only with pregnancy and diabetes mellitus. 
Insufficient magnesium impairs central nervous system activity and 
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increases muscular excitability because magnesium metabolism is 
intricately linked to calcium metabolism. Magnesium deficient clients 
display the signs of tetany. Other signs include disorientation, convulsions, 
psychosis. Relief of signs and symptoms may take 60-80 hrs after treatment 
begins32. 
Magnesium deficiency has been associated with insulin resistance, 
carbohydrate intolerance, cardiac arrhythmias, congestive heart failure, 
retinopathy and hypertension. The most common cause of 
hypomagnesaemia in diabetes mellitus is loss of magnesium through chronic 
glycosuria and diuretic use. A deficiency may lead to insulin resistance or 
may be a result of insulin resistance. Several studies have found that 
supplementation with magnesium can improve glucose control and insulin 
sensitivity. The American Diabetes association does not recommend routine 
evaluation of magnesium status in healthy individuals with diabetes but 
recommends routine evaluations for those people at high risk for magnesium 
losses, such as those with poor glycemic control, those receiving diuretics, 
those with intestinal malabsorption, those with calcium or potassium 
deficiencies and pregnant women33. 
GLYCOSYLATED HEMOGLOBIN (HbA1c): 
Glucose is bound to hemoglobin irreversibly by a continuous slow non 
enzymatic process resulting in the formation of glycosylated hemoglobin. 
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The percentage amount of hemoglobin that undergoes glycosylation to form 
HbA1c is directly related to the average concentration of glucose in the 
blood. In a normal person about 3-6 gm% of hemoglobin is glycosylated. In 
a diabetic the glycosylated hemoglobin may double or even triple. HbA1 is 
comprised of atleast 3 distinct sub-fractions: HbA1a, HbA1b and HbA1c. 
HbA1c is the major component and the fraction of clinical importance. The 
significance of HbA1a and HbA1b sub-fractions are not known and their 
correlation with long term glucose control is very questionable. Glucose 
combines by ketamine linkage to N-terminal valine as well as with lysine 
residues of both alpha and beta chains of hemoglobin. This reversible 
adducts (pre-HbA1c) can then undergo an amadori rearrangement to stable 
ketoamine (HbA1c). Pre-HbA1c formation will follow rapidly and 
proportionately to the amount of available glucose34. The circulating 
erythrocytes have a half-life of 60 days. So, HbA1c values will begin to 
reflect radical changes in diet or other modes of therapy approximately 3-4 
weeks after the initiation of diet or therapy. Unlike urine and blood glucose 
tests, HbA1c measurement is not a momentary look at sugar levels but an 
indicator of the average blood sugar concentration over the previous two or 
three months. HbA1c has the advantage of not influenced by diet, mode of 
therapy, physical activity, relations to meals and patient co-operation at the 
time of testing. HbA1c values may be misleading in conditions where life 
span of red blood cells is altered as in hemolytic disorders and 
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hemoglobinopathies. Glycosylated hemoglobin is not useful for day to day 
management and in adjusting the dose of insulin or oral anti-diabetic drugs. 
Along with HbA1c, blood glucose values must be available to the physician. 
It can be useful to distinguish stress hyperglycemia from pre-existing 
diabetes in situations of hyperglycemia associated with conditions like 
infection, myocardial infarction, stroke and surgery35. 
EFFECT OF TYPE 2 DM ON PERIPHERAL NERVES: 
Diabetic neuropathies have multifactorial pathogenic mechanisms, 
and varied clinical presentation. Chronic hyperglycemia plays a dominant 
role in the pathogenesis of diabetic neuropathy. Other metabolic 
consequences of hyperglycemia such as increased polyol pathway activity, 
myo-inositol depletion and Na+K+ATPase activity contribute to the 
pathogenesis of diabetic neuropathies. These pathogenic factors operating 
either individually or in combination contribute to the syndrome of diabetic 
neuropathy. 
The accumulation of sorbitol has deleterious effects on nerve 
conduction velocity. This is attributed to Schwann cell damage caused by 
increase in osmolarity due to sorbitol and fructose. Hyperglycemia causes 
increased intracellular concentrations of glucose, resulting in increased 
activity of polyol pathway. This acts through unknown mechanism leading 
to depletion of myo-inositol concentration which inhibits tissue Na+ K+ 
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ATPase activity. The synthesis of myelin which is rich in cholesterol, 
cerebroside and sphingomyelin and phosphotidyl serine-phosphotidyl 
inositol is likely to be reduced contributing to neuropathy. 
The normal vascular autoregulation is lost leading on to decreased 
endoneural blood flow and hypoxia. Though vascular and metabolic 
hypothesis for the pathogenesis of diabetic neuropathy has been postulated 
individually, more often there is an overlap of both metabolic and vascular 
events. Endothelial proliferation with luminal narrowing, hyperplasia of 
pericyte basement membrane and thickening of the perivascular space are 
frequently observed. Metabolic and vascular factors, together with 
glycosylation of proteins, hyperaggregation of platelets may all contribute to 
the development of neuropathy. 
ELECTROPHYSIOLOGICAL ABNORMALITIES:  
Nerve conduction studies are of great assistance in detecting 
neuropathy without having to resort to histopathological studies. In addition, 
conduction studies are extremely useful in confirming presence of focal 
nerve entrapments (carpal tunnel, cubital tunnel and common peroneal 
tunnel syndromes etc.). Newer techniques give a fairly accurate assessment 
of extent of neuropathy. Needle electromyography is a more recent and 
sophisticated test. Sensory nerve action potential and autonomic function 
tests are more sensitive in identifying subtle abnormalities of nerves in 
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diabetic neuropathy than motor conduction studies. Sequential EMG 
changes after axonal damage ranging from reduced recruitment of motor unit 
potentials occurring as early as 7 days to the presence of fibrillation 
potential, polyphasic high amplitude longer duration motor unit potentials, 
absent F waves reflecting changes occurring later in the course of the disease 
are recorded35. 
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COMPLICATIONS OF TYPE 2 DM 
Complications of type 2 DM is broadly classified into acute and chronic.  
Acute complications  
Diabetic ketoacidosis and Hyperglycemic Hyperosmolar state 
Chronic complications are classified into 
Microvascular and Macrovascular  
Microvascular complications  
Eye disease -Retinopathy, Macular edema  
Neuropathy -Sensory and Motor neuropathy, Autonomic 
neuropathy  
Nephropathy 
Macrovascular complications  
  Coronary artery disease, Peripheral arterial disease and 
  Cerebrovascular disease 
Others- periodontal disease, cataract, glaucoma, sexual dysfunction 
    gastroparesis, skin and systemic infections. 
The risk of chronic complications increases as the duration and degree 
of hyperglycemia increases. Randomized clinical trials in type 2 DM have 
demonstrated that a reduction in chronic hyperglycemia prevents or delays 
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retinopathy, neuropathy, and nephropathy. Some individuals with long-
standing DM never develop nephropathy or retinopathy. This precludes that 
there is some genetic susceptibility for developing particular complications. 
Coronary heart disease and related mortality rates are two to four times 
greater in patients with type 2 DM. These events correlate with fasting 
plasma glucose, postprandial plasma glucose, and HbA1c, hypertension and 
lipid levels36.  
THEORIES EXPLAINING THE EFFECT OF CHRONIC 
HYPERGLYCEMIA: 
(i) The increased intracellular glucose leads to the formation of 
advanced glycosylation end products, which bind to a cell surface 
receptor through non-enzymatic glycosylation. Non-enzymatic 
glycosylation results from the interaction of glucose with amino 
groups on proteins. These products cross-link proteins such as 
collagen, extracellular matrix proteins and accelerate 
atherosclerosis, promote glomerular dysfunction, reduce nitric 
oxide synthesis, induce endothelial dysfunction, and alter 
extracellular matrix composition and structure.  
(ii) A second theory is that chronic hyperglycemia increases glucose 
metabolism via the sorbitol pathway. Intracellular glucose when it 
reaches a level above which glycolysis is impossible within the 
48 
 
cells, is converted to sorbitol by the enzyme aldose reductase. 
Sorbitol accumulates inside the cell and alters redox potential, 
increases cellular osmolality, generates reactive oxygen species, 
and ultimately leads to cellular dysfunction. Aldose reductase 
inhibitors have no proven effect on the complications of diabetes 
mellitus. 
(iii) A third theory is that chronic hyperglycemia increases the 
formation of diacylglycerol. Diacylglycerol activates protein 
kinase C which causes transcription of genes for fibronectin, type 
IV collagen, contractile proteins, and extracellular matrix proteins 
in endothelial cells and neurons. 
(iv) Chronic hyperglycemia generates fructose-6-phosphate through 
hexosamine pathway. This alters function of cell by glycosylation 
of endothelial nitric oxide synthase and by changes in gene 
expression of transforming growth factor and plasminogen 
activator inhibitor-1. 
Vascular endothelial growth factor-A, platelet-derived growth factor, 
epidermal growth factor, insulin-like growth factor I, growth hormone, basic 
fibroblast growth factor, and even insulin, have been suggested to play a role 
in DM-related complications.   
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NEUROPATHY IN DIABETES MELLITUS 
STAGES OF DIABETIC PERIPHERAL SENSORY NEUROPATHY: 
Stages of neuropathy Characterisitics 
No neuropathy No symptoms or signs 
Clinical neuropathy 
  Chronic painful 
 
 
 
  Acute painful 
 
Burning/shooting/stabbing 
pain;±pins and needles; increased at 
night; absent sensation to several 
modalities; reduced/ absent reflexes 
Severe symptoms as above; may 
follow initiation of insulin in poorly 
controlled diabetes; signs minor or 
absent 
Painless with complete/partial 
sensory loss 
Numbness/deadness of feet or no 
symptoms; painless injury; 
reduced/absent sensation; reduced 
thermal sensitivity; absent reflexes 
Late complications Foot lesions; neuropathic 
deformities; non-traumatic 
amputations. 
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CLINICAL FEATURES OF DISTAL SENSORIMOTOR DIABETIC 
NEUROPATHY 
Large fibre type Small fibre type 
Unsteady gait Pain predominates  
Absent reflexes Variable reflexes 
Decreased vibration/position sense Variable position/vibration sense 
Charcot’s joints possible Variable presence of Charcot’s 
joints 
Mimics posterior column lesions Ultimately leads to sensory loss 
 
AUTONOMIC NEUROPATHY 
Conventionally, diagnosis of autonomic neuropathy is based on 
simple tests using cardiovascular reflexes during deep breathing, standing, 
Valsalva maneuver and blood pressure response to standing and sustained 
handgrip. Tests involving parasympathetic nerves show abnormalities 
earlier than those involving sympathetic. Loss of sweating in the feet and 
impotence may precede abnormal cardiovascular tests. Diabetic with 
autonomic neuropathy are prone for sudden death from painless myocardial 
infarction and cardiorespiratory arrest. Generally, symptoms due to 
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autonomic neuropathy include postural hypotension, gustatory sweating, 
diarrrhoea, unawareness of hypoglycemia; bladder dysfunction, impaired 
temperature regulation and altered sweating. Delayed gastric emptying, 
marked retention and patulous pylorus(gastroparesis diabeticorum), disorder 
of esophageal motility, bladder paralysis resulting in urinary retention with 
superimposed infection and sexual dysfunction contribute significantly to 
the morbidity in subjects with autonomic neuropathy. Pupillary 
abnormalities namely a reduction in the resting pupil size, loss of 
spontaneous oscillations (hippus), loss of light reflex and occasionally loss 
of accommodation reflex are observed. Very rarely, a true Argyll-Robertson 
pupil is seen35. 
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RELATED  STUDIES 
Chandrashekar M Sultanpur et al37 did a review on glycosylated 
hemoglobin in the diagnosis of diabetes mellitus.  A normal non-diabetic 
HbA1c is 3.5-5.5%.The IDF and American College of Endocrinology 
recommend HbA1c values below 6.5%, while ADA recommends that the 
HbA1c to be less than 7.0% for most patients. On average, HbA1c of 6% 
corresponds to mean plasma glucose of 135 mg/dl of blood. Vitamins C and 
E have been reported to lower HbA1c measurements by inhibiting 
glycosylation. Alcoholism, lipidemia, and chronic ingestion of salicylates, is 
also known to reduce the level of HbA1c. Higher levels of HbA1c level can 
be seen in people with a longer red blood cell life span, such as with Vitamin 
B12 or folic acid deficiency. There is also some evidence of wide 
fluctuations in HbA1c between individuals. There are two groups based on 
this called as “low glycators” and “high glycators”. When the HbA1c and 
fructosamine levels are measured simultaneously, HbA1c does not 
accurately reflect glucose control. So measurement of fructosamine was 
suggested to be routinely used in clinical practice. They also added that 
HbA1c level cannot be used as a sole tool for assessing the diabetic status. 
The additional peaks that occur in HPLC’s lead to overestimation and 
underestimation of HbA1c results. Electrospray mass spectrometry and a 
method based on quenching of the fluorescence of an eosin-boronic acid 
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solution ate newer methods. The immunoagglutination method called the 
DCA 2000 uses a specific antibody against the first six amino acid residues 
of the glycated N-terminal of hemoglobin. This method suggests that only 
few hemoglobin variants are known to interfere with HbA1c results. 
Firas Salih Abdul Hadi et al38 did a study to investigate the effects of type 
2 DM on the levels of HbA1c, testosterone and calcium with relationship of 
leptin on 45 diabetic male patients and 20 apparently healthy controls. It was 
conducted at Specialist Center for Endocrine and Diabetes Diseases in 
Baghdad province. The age of men ranged 25-54 years.  Calcium levels 
showed significant (p<0.05) decreasing (2.26±0.03) in non-obese T2DM in 
comparison with control group (2.39±0.03) and obese T2DM (2.30±0.04) 
but the value was within normal range (2.0-2.6mmol/l). 
Rajni Dawar Mahajan et al39 reviewed several published articles to 
analyze the importance of using HbA1c for diagnosing Diabetes mellitus in 
India. At the end of their review they concluded that in the present Indian 
scenario Glycated hemoglobin should not be accepted as an independent test 
to diagnose type 2 DM. A similar analysis was done by Chris Florkowski40. 
The study concluded that HbA1c can be a diagnostic test provided it should 
be measured in a laboratory using a National Glycohemoglobin 
Standardization Program-certified assay, and also stressed that in the 
absence of unequivocal hyperglycemia the test should be repeated. 
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Zaccardi F et al41 did a prospective study in which ionized calcium and 
cardio metabolic risk factors were identified in a population-based sample 
of 2350 men without a known history of type 2 DM at the start. The 
associations between ionized calcium levels and incident cases of type 2 DM 
were estimated using Cox regression analyses adjusted for potential 
confounders.  After a median follow-up of 23.1 years, 140 new cases of type 
2 DM were recorded. A multivariable analysis adjusted for age, BMI, 
systolic blood pressure, serum HDL-cholesterol, and family history of type 
2 DM was done and they could not find an association between ionized 
calcium and future risk of type 2 DM. 
Kanchana et al42  in their comparative  study of calcium and vitamin D 
levels in diabetics and non-diabetics have found an inverse relationship 
between serum calcium and blood glucose level. 
D.S. Pushparani et al43 in their research evaluated the serum level of 
calcium and iron in type 2 diabetes mellitus with periodontitis subjects. A 
total of 450 subjects participated in the study. They were equally distributed 
into three groups as control healthy individuals, type 2 DM without 
periodontitis, and type 2 DM with periodontitis. They were matched for age, 
sex, and duration of diabetes mellitus. According to Newman-Keuls 
Multiple Comparison test, the means levels of serum Calcium of group II 
was lesser than the means of all other groups. The mean calcium level in 
type 2 DM with periodontitis (group III) was significantly higher when 
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compared to control. However, in the case of type 2 DM without 
periodontitis, the serum Ca levels were decreased non-significantly. 
Anubha Shukla et al44 reviewed the significance of Calcium and Vitamin 
C in maintaining glucose homeostasis. They pinned that the increased blood 
glucose levels can inhibit calcium entry into cells thus causing decreased 
insulin secretion. 
Mohamed Murtuza Kauser et al45 in their study compared 50 diabetics and 
50 non-diabetics to identify serum magnesium levels. The serum magnesium 
levels in the Oral Hypoglycemic Agent group, insulin group and the insulin 
plus Oral Hypoglycemic Agent group were 2.02 mg/dl, 1.59 mg/dl and 1.25 
mg/dl respectively. The study showed significant decrease in serum 
magnesium in type 2 DM as compared to controls. The conclusion was 
hypomagnesaemia may be a contributing factor for the long term 
complications particularly relating to eyes and heart. 
Prabhu G et al46 had done a prospective study in 132 Type 2 DM patients. 
Serum magnesium level was estimated and compared with the age matched 
control group. In their study the serum magnesium levels varied between 1.1 
to 3.1 mg/dl against the normal laboratory value of 1.5 -2.5 mg/dl. 33(25%) 
of the study group had low serum magnesium levels(less than or equal to 
1.5mg/dl). This led to an assumption that serum magnesium was lower in 
patients when the duration of the disorder increased. The correlation between 
hypomagnesaemia and poor glycemic control was statistically significant.   
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Pramod P Rao and Mohamed Ghouse Shariff’s study47 was to know the 
status of serum magnesium in microalbuminuric and normoalbuminuric 
Type 2 DM patients.  100 patients of Type 2 Diabetes mellitus attending 
outpatient/inpatient clinic were grouped into equal groups of 50 patients into 
microalbuminuria and normoalbuminuria. Fasting blood sugar, postprandial 
blood sugar, HbA1C, renal function test, spot urine albumin creatinine ratio, 
serum electrolytes including Magnesium levels were compared in both 
groups. About 6% of microalbuminuria had hypomagnesemia, and one 
patient had hypomagnesemia. They concluded that low magnesium levels 
were significantly associated with poor glycemic control and 
microalbuminuria levels were higher when compared to patients with normal 
magnesium levels. Retinopathy was also significantly associated with 
hypomagnesemia. Therefore, screening for serum magnesium levels in Type 
2 DM and its correction may help in achieving better glycemic control, 
which can prevent further diabetic complications. 
In a study by Sasmita Mishra et al48 there was a positive correlation 
between high density lipoprotein and serum magnesium. There happened to 
be a negative correlation between low density lipoprotein, triglycerides and 
serum magnesium in the type 2 DM subjects. 
Serum magnesium levels were compared between pre-diabetics and healthy 
age matched individuals in the study by K. Sumathi and A. Mary 
Chandrika49. They identified hypomagnesemia in diabetics and proposed 
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the value of magnesium supplementation in type 2 DM. S. Ramdass et al50 
categorized the study population of type 2 DM subjects into three types 
based on their glycemic control and estimated serum magnesium levels. It 
was found that magnesium was reduced in the group which had a poor 
control in the blood glucose levels.  
Abhijeet A. Adgaonkar et al51 in their study “Clinical Profile of Peripheral 
Neuropathy in Diabetes Mellitus by Nerve Conduction Study” included 50 
subjects with type 2 DM. They included subject from both sex and different 
age group ranging from 20 to 70 years with varying period of disorder. They 
assessed  involvement of peripheral nerves both clinically as well as with 
nerve conduction study. They found that the incidence of peripheral 
neuropathy was recorded as 30% on clinical examinations. Whereas on 
nerve conduction study it was found 42 %. They concluded that diabetic 
peripheral sensory motor peripheral neuropathy was the commonest type of 
presentation and the lower limbs were almost always affected and the upper 
limbs were less affected. The similar study by Yacoub G Bahou et al52 also 
had the similar presentation and results. 
Arindam Dutta et al53 did a study entitled “Prevalence of peripheral 
neuropathy in newly diagnosed type 2 diabetics”. 100 newly diagnosed type 
2 diabetic patients attending the Diabetes clinic were taken for the study. 
Multiple logistic regression analysis showed that duration of diabetes had 
highest contribution and age, and blood glucose have some contribution. The 
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prevalence of peripheral neuropathy in newly diagnosed type 2 diabetic 
patients using clinical and electrophysiological methods was 29%. They 
ended that there was a significant correlation between peripheral neuropathy 
and duration of diabetes, age of the patients and fed-state blood glucose 
levels. 
Kanavi Roopa Shekharappa et al54 did a study on “The Utility of Nerve 
Conduction studies in type 2 DM”. 45 patients with normal HbA1c and 45 
patients with elevated HbA1c levels were included. Analysis revealed that 
conduction of nerves progressively decreased from patients with good 
glycemic control to those with poor glycemic control. They concluded that 
the nerve conduction studies can be employed for diabetic patients who have 
early neuropathic symptoms. 
Vijay Viswanathan et al55 did “Nerve conduction abnormality study in 
different stages of glucose intolerance” in a Diabetes Research Centre. 225 
subjects were categorized into normal glucose tolerance, impaired glucose 
tolerance and asymptomatic newly diagnosed type 2 DM patients. Motor and 
sensory nerve conduction velocities were measured. The motor nerve 
conduction velocity demonstrated by IGT subjects were slower and so they 
concluded that type 2 DM subjects need an early screening  for 
complications. 
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MATERIALS AND METHODS 
STUDY DESIGN: This was a cross-sectional study. 
STUDY CENTRE AND PERIOD: This was conducted in Tirunelveli 
medical college Hospital from November 2015 to August 2016. 
SAMPLE SIZE: The sample size was 75.  
STUDY GROUP: The study group was divided into two categories.  
 First group - Newly diagnosed type 2 DM patients which included 25 
female and 20 male patients 
 Second group – Type 2 DM patients who were taking treatment for 
more than five years which included 15 female and 15 male patients. 
ETHICAL CONSIDERATIONS: 
Approval from institutional ethical committee of Tirunelveli Medical 
College was obtained. The procedure was explained in detail to all subjects 
in their own local language. Written informed consent was obtained from 
those persons who were willing to undergo this study. 
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INCLUSION CRITERIA: 
 Newly diagnosed type 2 DM patients- involved male and female 
patients who were diagnosed to have type 2 DM for less than a year 
and were on regular treatment. 
 The other group was male and female patients with type 2 DM who 
were diagnosed to have the disease for more than 5 years and was on 
regular treatment. 
EXCLUSION CRITERIA: 
 Type 2 DM patients who were on irregular treatment. 
 Hypertensive patient 
 Patients with preexisting neurological disorders 
 Pregnant women 
 Smoking and alcohol intake 
 Use of drugs causing neuropathy 
 Liver and kidney disease 
 Family history of neuropathy 
 
Each person had a separated format wherein personal details, family 
history and history of illnesses were recorded. It also included 
anthropometric measurements. 
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              ERBA CHEM – 5 SEMI-AUTOMATED ANALYZER 
 
 
               COLLECTION OF VENOUS BLOOD SAMPLE 
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STUDY METHODS: 
First, the patients were interrogated about their personal history, 
medical history, treatment history and family history relating to type 2 DM. 
Second, they were taken to the Central Diagnostics Laboratory for blood 
collection. Patients were asked to relax and be seated comfortably. Then, 
following universal precautions 5 ml of blood sample was obtained from 
antecubital vein for estimation of serum magnesium, serum calcium, HbA1c. 
Serum was separated using a centrifugation machine for estimation of 
calcium and magnesium. 
Subsequently they were directed to the Neurophysiology Lab for 
nerve conduction study. 
 HbA1c (ERBA) – Particle enhanced Immuno-turbidimetric method 
was employed. IFCC reference method is used. It is applicable for 
hemoglobin values ranging from 6-26 gm%. HbA1c measuring range 
was 3.98-15.42%. HbA1c was determined using CHEM-5 semi-
automated analyzer. 
 Calcium (LABCARE)- Calcium with Arsenazo III at neutral pH yield 
a blue coloured complex. The intensity of colour was proportional to 
calcium levels. Serum reference values 8.8-10.2 mg/dl. Serum 
calcium was determined using CHEM-5 semi-automated analyzer. 
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 Serum magnesium was determined photocolorimetrically using kit 
method in CHEM-5 semi-automated analyzer. The normal range is 
1.9-2.5 mg/dl. 
 BASIC COMPONENTS OF NERVE CONDUCTION RECORDING 
EQUIPMENTS: 
Electro diagnostic equipments consist of both stimulating and 
recording systems, amplifiers, filters, microprocessor and video and audio 
monitors in addition to computers. 
STIMULATING SYSTEM: 
The primary function of a nerve is the transmission of an electrical 
impulse from one source point to another. The stimulus usually travels from 
the nerve cell body or from sensory receptors. But, in nerve conduction 
studies the nerve is stimulated by an external electrical source. When the 
nerve is near the surface of the body, skin electrodes are enough to record 
the electrical impulse. Whereas, deeper nerves require needle electrodes. 
During surgery, stimulating electrodes are applied directly over the exposed 
nerves. To obtain a maximal response, all nerve fibres are stimulated by 
using supra maximal stimulus. Sub maximal stimulus gives rise to false 
results. 
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NERVE CONDUCTION STUDY 
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RECORDING SYSTEM: 
The electrodes are 
• Surface electrodes 
• Needle electrodes. 
There are three types of surface electrodes. They are disc, cup and ring 
electrodes. Disc electrodes are used in nerve conduction studies and motor 
evoked potentials and cup electrodes in other evoked potentials. Needle 
electrodes are employed in electromyography and in some situation in nerve 
conduction and evoked potential studies. The electrodes are made with 
various types of metal and alloys. Silver chloride electrodes record noise free 
stable polarization potentials. Three electrodes are used as the components 
of the recording systems in neuro physiological studies. They are active, 
reference and ground electrodes. Reference electrode is placed over the 
tendons. Between stimulator and the recording electrodes the ground 
electrode is applied. Both active and reference electrodes are kept over the 
nerves in sensory nerve conduction studies. Amplitude of CMAP or SNAP 
is altered if the distance between the active electrode and reference electrode 
is changed. The recommended inter electrode distance in sensory conduction 
studies is 4 cms.  
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PARAMETERS MEASURED IN NERVE CONDUCTION STUDY: 
In both motor and sensory conduction studies, 
• Latency 
• Amplitude 
• Conduction velocity are the parameters used for interpretation of results. 
NERVE CONDUCTION STUDY:  
The study subjects were explained about the procedures. The nerve 
conduction study was performed in left median nerve of upper limb and left 
sural nerve of lower limb to assess sensory components. The nerve examined 
for the motor nerve conduction study was left median nerve. 
EQUIPMENT USED:  
The nerve conduction study was done using RMS(Recorders and 
Medicare Systems) EMG EP MARK II at Neurophysiology unit of the 
neurology department. Surface electrodes were used. For motor nerve 
conduction study, the low filter-2Hz and high filter-3 kHz was used. For 
sensory nerve conduction study the low filter-20 Hz and high filter-3 kHz 
was used. The room temperature was maintained between 23-25 degree 
celcius. Initially nerves were stimulated with low voltage strength of current 
and gradually increased till we obtained a maximal response curve.  
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PREPARATION:  
The skin was cleaned with the spirit and allowed to dry. Skin 
preparation is essential to provide a good contact between the skin and the 
electrodes and to eliminate artifacts. The electrodes were soaked in normal 
saline to minimize skin resistance thereby facilitating conduction. Adequate 
electrode gel should be applied to the recording electrodes used in motor 
conduction study while fixing it to the skin. Correct placement of electrodes 
is also important.  
SENSORY CONDUCTION STUDY:  
The electrodes were attached to their respective site after preparation 
of both skin and electrodes and the nerves were stimulated at a single site 
.The recording electrodes were ring electrodes. The antidromic sensory 
conduction study was done.  
MEDIAN NERVE (Sensory):  
1) The site of placement of active electrode was proximal inter phalangeal 
joint of the left second finger.  
2) The reference electrode was placed on the last phalanx of the same 
finger.  
3) The ground electrode was over the dorsum of the hand.  
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  MEDIAN NERVE (MOTOR) CONDUCTION GRAPH 
 
 
 
           F-WAVE 
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4) Nerve stimulation was carried out at the wrist between the tendons of 
palmaris longus and flexor carpi radialis , at the 2nd  distal most creases.  
5) Peak latency of less than 3.1 ms and minimum conduction velocity and 
amplitude of 50 m/sec and 30 µv respectively were taken as normal 
parameters.  
SURAL NERVE (Sensory):  
1) Active electrode was placed between the left lateral malleolus and the 
achilles tendon at the malleolar level 
2) The reference electrode was placed 3 cm distal to the active electrode. 
3) Nerve stimulation was done at a point which is distal to the lower border 
of the bellies of the gastrocnemius muscle but 10 to 16 cm above the 
lateral malleolus just lateral to the midline. 
4) We used maximum latency of 4.0 ms and minimum conduction 
velocity of 48 m/sec and minimum amplitude of 8 µv as normal values. 
MOTOR CONDUCTION STUDY:  
After adequate preparation, the recording electrodes were attached to 
the correct position with reference to the nerve to be studied. The nerves 
were stimulated in two points. The distance between the two points of 
stimulus application was measured and entered for calculation of conduction 
velocity.  
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MEDIAN NERVE:  
1. Active electrode was placed over Abductor pollicis brevis    
2. Reference electrodes were placed over the muscle tendon  
3. Ground electrode was kept over the dorsum of  hand. 
4. Nerve was distally stimulated at the wrist between the tendons of 
palmaris longus and flexor carpi radialis tendons at the second crease.  
5. For proximal stimulation of nerve, the stimulator was placed at the 
elbow crease, medial to the biceps tendon and brachial artery. 
6. Normal values are maximum onset latency of 3.4 ms and minimum 
conduction velocity and amplitude of 53m/s and 4 mV respectively. 
F wave latency was recorded by stimulating the nerve at the distal point to 
get 10 to 20 F waves56. 
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STATISTICAL ANALYSIS 
Databases of all personal details such as age, sex, weight and height, 
laboratory values such as HbA1c, serum calcium, serum magnesium and 
nerve conduction study values such as latency, conduction velocity and 
amplitude for the peripheral nerves under study were entered in Microsoft 
Excel sheet and a master chart was prepared.  Statistical analysis of all study 
databases were performed by IBM SPSS version 20.0 software. 
Mean (SD) and frequency (percentage) were used to describe the 
summary data. Two sample ‘t’ test was used to compare the mean difference 
between groups. Pearson correlation analysis was used to check the 
correlation between nerve conduction parameters such as latency, 
conduction velocity and amplitude with laboratory parameters. ‘P’ value less 
than 0.05 was considered as statistically significant.  
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Table 1: Age distribution among the two study groups 
Age( years) Mean(SD) Range p value 
Group I (n=45) 45.60(4.2) 38 – 56 
<0.001* 
Group II  (n=30) 51.27(7.0) 38 – 65 
 
*p value< 0.05 is statistically significant 
Figure: Mean of age distribution in the two study groups 
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Figure: Percentage distribution of sexes in the two groups 
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Table 2: Comparison of means of HbA1c, Serum Magnesium and 
Serum Calcium 
Variable 
Group1 (n=45) Group2 (n=30) 
p value 
Mean (SD) Range Mean (SD) Range 
HbA1c 6.37(0.8) 4.8 – 7.9 7.09(0.9) 4.6 – 8.9 <0.001* 
Sr.Cal2+ 9.05(0.7) 8.0 – 10.5 9.07(0.6) 8.0 – 10.6 0.897 
Sr.Mg2+ 2.21(0.3) 1.5 – 2.9 1.94(0.3) 1.4 – 2.5 0.001* 
*p <0.05 is statistically significant 
 Figure: Mean of HbA1c in the two groups compared with bar diagram  
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Figure: Comparison of means of serum calcium in the two groups  
 
Figure: Comparison of means of serum magnesium in the two groups  
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Table 3: Parameters of Median Nerve (Sensory) conduction 
Median 
Nerve 
Sensory 
Group1 (n=45) Group2 (n=30) 
p value Mean 
(SD) 
Range Mean 
(SD) 
Range 
 
     LAT 
     AMP 
     CV 
 
2.31(0.2) 
34.74(2.8) 
56.16(1.7) 
 
1.95 – 2.84 
30.25 – 40.45 
52.12 – 59.43 
 
2.61(0.5) 
32.18(2.0) 
52.36(1.9) 
 
2.03 – 3.65 
28.54 – 35.86 
48.75 – 55.67 
 
0.001* 
<0.001* 
<0.001* 
*p <0.05 is statistically significant 
Figure: Median nerve (Sensory) conduction parameters between groups 
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              Table 4: Parameters of Median Nerve (Motor) conduction 
Median 
Nerve 
Motor 
Group1 (n=45) Group2 (n=30) 
p value 
Mean(SD) Range Mean(SD) Range 
 
LAT 
AMP 
CV 
FW LAT 
 
2.69(0.5) 
5.74(0.5) 
59.23(1.7) 
22.98(0.4) 
 
1.80 – 3.97 
4.58 – 7.00 
57 – 63.45 
22.05 – 24.12 
 
3.14(0.2) 
5.61(0.5) 
53.70(2.3) 
24.53(1.0) 
 
2.67 – 3.45 
4.35 – 6.86 
50.35 – 59.23 
23-26.32 
 
<0.001* 
0.318 
<0.001* 
<0.001* 
*p <0.05 is statistically significant      
Figure:  Median-motor nerve conduction parameters between groups 
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              Table 5: Nerve conduction parameters of Sural Nerve (Sensory) 
Sural 
Sensory 
Nerve 
Group1 (n=45) Group2 (n=30) 
p value 
Mean(SD) Range Mean(SD) Range 
 
LAT 
AMP 
CV 
 
3.09(0.3) 
10.37(1.3) 
51.22(1.7) 
 
2.39 – 3.98 
8.32 – 14.25 
47.21 – 54.5 
 
3.23(0.4) 
8.95(0.7) 
48.27(1.8) 
 
2.39 – 3.96 
7.60 – 10.5 
45.25 – 52.37 
 
0.123 
<0.001* 
<0.001* 
        *p <0.05 is statistically significant   
Figure: Sural nerve (Sensory) conduction parameters between groups 
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Table 6: Pearson correlation of Median Nerve (Sensory) conduction 
with HbA1c 
Median Nerve 
Sensory 
Group 1 Group 2 
Correlation 
coefficient 
p value Correlation 
coefficient 
p value 
LAT 0.5313 <0.001 -0.0261 0.891 
AMP -0.4601 0.002 -0.6915 <0.001* 
CV -0.0429 0.780 -0.3291 0.076 
*p <0.05 is statistically significant 
SCATTER DIAGRAM 
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Table 7: Pearson correlation of Median Nerve (Motor) conduction 
with HbA1c 
Median Nerve 
Motor 
Group 1 Group 2 
Correlation 
coefficient 
p value Correlation 
coefficient 
p value 
 LAT -0.1081 0.479 0.2516 0.180 
 AMP -0.1150 0.452 0.0527 0.782 
 CV 0.0152 0.921 -0.2233 0.236 
 FW LAT -0.1408 0.356 0.2439 0.194 
 
Table 8: Pearson correlation of Sural Nerve (Sensory) conduction with 
HbA1c 
Sural Nerve 
Sensory 
Group 1 Group 2 
Correlation 
coefficient 
p – value Correlation 
coefficient 
p value 
 LAT 0.0179 0.907 0.2361 0.209 
 AMP -0.0696 0.650 0.0212 0.912 
 CV 0.0044 0.977 -0.0967 0.611 
 
  
81 
 
Table 9: Pearson correlation of HbA1c with BMI & Sr. Magnesium 
Variable 
Group 1 Group 2 
Correlation 
coefficient 
p value Correlation 
coefficient 
p value 
BMI 0.4015 0.006* 0.0868 0.649 
Sr. Mg2+ -0.6058 <0.001* -0.3482 0.059 
*p <0.05 is statistically significant 
SCATTER DIAGRAM 
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Table 10: Correlation of serum magnesium with nerve conduction 
parameters in first group 
 Median N. Sensory Median N. Motor Sural N. Sensory 
 Lat Amp CV Lat Amp CV FWLat Lat Amp CV 
Sr. 
Mg2+ 
-0.533 0.471 0.094 -0.16 0.313 0.178 -0.093 -0.28 0.029 0.082 
 
 
Table 11: Correlation of serum magnesium with nerve conduction 
parameters in second group 
 Median N. Sensory Median N. Motor Sural N. Sensory 
 Lat Amp CV Lat Amp CV FWLat Lat Amp CV 
Sr. 
Mg2+ 
-0.27 0.163 0.607 0.217 -0.107 0.232 0.086 -0.071 0.177 0.028 
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DISCUSSION 
 In the first group i.e. newly diagnosed type 2 DM, age distribution 
ranged from 38 years to 56 years whereas, in the second group the age 
distribution ranged from 38 years to 65 years. The mean age of group 
I was 45.6 and group II - 51.27 years. So, this would very clearly 
elucidate that even though the study population was small it 
comprised of diabetic patients more in the fourth decade of life. So, 
type 2 DM is not a disease of old age as previously thought.  
 In group I, the female population was little bit higher than male 
population whereas in group II both sexes were distributed equally. 
This unequal distribution of sex in group was not done in purpose 
rather, it happened purely by chance as the female patients who visited 
the clinic were more compliant. The sample size of the study was fixed 
to a smaller size as the title under study was a common disorder in the 
general population. The results of a smaller population would reflect 
the disease burden of the entire affected population. 
 The range of HbA1c in group I was 4.8-7.9 with a mean of 6.37±0.8. 
The range of HbA1c in group II was 4.6-8.9 with a mean of 7.09±0.9. 
The means of the two groups were compared and found to be 
statistically significant with a ‘p’ value <0.001. The mean of HbA1c 
values for group II was 7.9, a value which crossed the target level of 
good glycemic control in patients with type 2 DM. 
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HbA1c was used to diagnose diabetes as early as 1980’s, but there 
were several issues regarding its availability and poor standardization. So, 
there was hesitancy in using it as the diagnostic tool. In 2009 an international 
expert committee recommended HbA1c as a diagnostic method for diabetes. 
It recommended a threshold level of ≥6.5%. This recommendation was 
adopted by the American Diabetes Association57and by World Health 
Organization. HbA1c values indicate chronic hyperglycemia i.e. values for 
2-3 months rather than hyperglycemia at a particular point of time. It gives 
an integrated index of glycemic status of the individual over the entire 120-
day lifespan of the red blood cell. The current HbA1c value reflects 50% of 
HbA1c formed in the month prior to sampling.  25% of HbA1c values reflect 
the glycosylation that occurred in the month before that. The test’s accuracy 
is affected by conditions that affect red blood cell life span or non-enzymatic 
glycosylation of hemoglobin. A reduced red blood cell survival time will 
lower the HbA1c level and may lead to a false negative result. Red blood 
cell survival time is reduced in hemolytic anemia, chronic renal failure, and 
severe liver disease, anemia of chronic disease, vitamin B12 and folic acid 
deficiencies. Patients who undergo regular phlebotomy for medical illnesses 
like hemochromatosis have false low values. Iron deficiency may also have 
an impact on red blood cell survival and increase the HbA1c level. 
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 Serum calcium in group I was 8.0-10.5 mg/dl with a mean of 9.05±0.7 
mg/dl. The range of serum calcium in group II was 8.0-10.6 with a 
mean of 9.07±0.6.The range and mean of both groups were within 
normal limits and the variations within the normal range between the 
groups could not be proved statistically significant. So, in our study 
serum calcium was not correlating with the glycemic control of the 
subjects. 
Nerea Becerra-Tomas et al58 in their study on 7,447 patients who had any 
cardiovascular risk factor proved a positive association of increased serum 
calcium and insulin resistance. It was a longitudinal study which found a link 
between changes in albumin-adjusted serum calcium concentrations and 
occurrence of diabetes mellitus. Their results showed that an increase in 
albumin-adjusted serum calcium levels during follow-up was associated 
with an increased risk of diabetes. In the study by Yamaguchi T et al59 
serum calcium was positively correlating with the fasting plasma glucose in 
type 2 DM. In the cohort study of Kim MK et al60 abnormal calcium 
homeostasis proves to have an effect on the occurrence of metabolic 
syndrome and type 2 DM. 
 The range of serum magnesium in group I was 1.5-2.9 mg/dl with a 
mean of 2.21±0.3. The range of serum magnesium in group II was 
1.4-2.5 mg/dl with a mean of 1.94±0.3. On comparing the means of 
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the two groups they were statistically significant with a ‘p’ value of 
0.001. This very well proves that in our study as the duration of 
diabetes mellitus increases the serum magnesium level decrease.  
 
 Nehal Hamdy El-said et al61 in their study “Magnesium in type 2 diabetes 
mellitus and its correlation with glycemic control” was done to compare 
serum magnesium levels in type 2 diabetes mellitus patients with non-
diabetic healthy control subjects. 60 type 2 diabetic patients and 30 healthy 
age matched control subjects were enrolled. Fasting blood sugar, fasting 
insulin, fasting lipids, HbA1C and serum magnesium were measured. Serum 
magnesium levels were significantly reduced in type 2 DM patients when 
compared with the control group. After completion of their study they 
recommended to measure serum magnesium in type 2 DM patients who need 
supplementation. Case control study by A.G. Kulkarni et al62 showed 
significant reduction in magnesium levels in type 2 DM when compared with 
aged matched non-diabetics. 
Dana Hyassat et al63 in their cross-sectional study conducted at the National 
Center for diabetes, Endocrinology and Genetics in Amman-Jordan 
performed a comparison of the prevalence of hypomagnesaemia between the 
studied sample and 3600 individuals enrolled in the National Vitamin D 
study completed in Jordan in 2009. A total of 1105 patients with type 2 
diabetes who attended the center between first of October 2011and end of 
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February 2012 were included in the study. Out of 1105 patients with type 2 
diabetes, 210 patients (19%) were diagnosed with hypomagnesemia. Female 
gender, hypertension, statin therapy, HbA1c between 7-7.9% or ≥ 9% and 
patients with diabetes duration more than five years were independent risk 
factors for hypomagnesaemia. No association between hypomagnesaemia 
and age distribution, smoking history, neuropathy and retinopathy was 
found. In comparison with individuals enrolled in the National Vitamin D 
study, diabetic patients in this study had a much higher prevalence of 
hypomagnesaemia. Studies by Ghasemi A et al64 and Arundhati Dasgupta 
et al65 showed that the serum magnesium decreased with poor glycemic 
control and with increased duration of type 2 DM diabetes mellitus which 
were similar to the findings present in our study. 
 
 On comparing the mean difference of the latencies of median sensory 
nerve between two groups, they were statistically significant. The 
latencies of the median sensory nerve were more prolonged in second 
group than in the first group. The amplitude and conduction velocity 
of the nerve is decreased more in the second group. These results 
indicate us that the duration of type 2 DM had a serious impact on 
nerve conduction parameters. 
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These above findings in our study was readily comparable with the results 
of a study by Nidhi Yadav et al66 in which the diabetes patients had a 
duration of more than five years duration and the latencies of the nerves were 
prolonged whereas the amplitude and velocities of the nerves decreased 
proportionately. 
 The analysis of parameters median nerve motor component the distal 
latency and F-wave latency increased in both groups. The amplitude 
and conduction velocity decreased in both groups. The distal latency, 
conduction velocity and F wave latency were statistically significant 
on comparison of mean difference between the two groups. The 
decrease in F wave latency was more significant in our study. 
Farah Nabil Abbas Al-Sadik’s67 study was on “The Value of Nerve 
Conduction Study and F-Wave Latency in Subclinical Neuropathic Type II 
Diabetic Patients”. Two subjects groups included in this study were patients 
with DM and control subjects. The routine nerve conductive study and F-
wave were conducted in 35 patients with type II diabetes mellitus but 
without symptoms and signs of lesions of nervous system. Conduction 
velocity and sensory amplitude were measured for median, ulnar and sural 
nerves as well as distal motor latency, motor conduction velocity, motor 
amplitude and F-wave latency were measured for median, ulnar and tibial 
nerves in DM patients and their control group. The distal sensory latency of 
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the median nerve was prolonged and the sensory conduction velocity was 
significantly decreased in diabetic patients (<0.05) when compared with the 
control group as well as the F-wave of the median nerve was significantly 
prolonged. There was a significant prolongation of F-wave latency regarding 
the nerves of both upper and lower extremities. The main advantage of F-
wave methodology was in the identification of peripheral neuropathies in 
which F-wave showed clinically significant and measurable changes even 
before conventional nerve conduction studies were informative. Neelamba 
Prasad et al68 conducted a “Comparative analysis of electrophysiological 
parameters of median nerve in normal and diabetic subjects”. Motor nerve 
conduction study of median nerve was performed on both sides of the body. 
40 male diabetes mellitus subjects with relatively short duration of disorder 
(2.28 ± 1.51 years) were compared with 40 non-diabetes mellitus subjects of 
same age group, BMI and sex. It was found that motor distal latency of (right 
and left) median nerves in diabetics was statistically significant when 
compared with non-diabetics. Results showed a decrease in amplitude and 
conduction velocities of both median nerves in diabetes mellitus patients. It 
was statistically significant. Latency was found to be positively correlated 
with blood sugar. Amplitude, conduction velocity was found negatively 
correlated with blood sugar. 
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 In our study, the sural nerve conduction parameters revealed a 
statistical significance in amplitude and conduction velocity but not in 
the latency. However, the mean latency was not much increased as 
expected in the second group and so the comparison of mean 
difference in latency between the two groups proved to be 
insignificant. Of the three parameters analyzed the amplitude and 
velocity of sural nerve was comparable with the other studies. 
Marta Banach69 did a study “To establish the prevalence and type of 
peripheral neuropathy in diabetic patients by determining the means of nerve 
conduction studies”. A total of 21 patients with type 2 DM presenting with 
neuropathy symptoms were enrolled in the study. Sensory and motor nerve 
conduction studies were conducted in the ulnar, median, peroneal, sural, and 
tibial nerves. The study revealed that 12 patients had nerve conduction 
abnormalities suggesting peripheral neuropathy and polyneuropathy. A 
reduction in the amplitude of sensory nerve action potentials (SNAP’s) and 
compound muscle action potentials (CMAP’s) in the lower limbs was the 
most common finding. In addition, their study confirmed that nerve 
conduction studies are useful in assessing the prevalence of neuropathy and 
differentiating between axonal and demyelination polyneuropathies. It also 
emphasized that nerve conduction studies should be part of routine primary 
care strategies in the management of diabetes mellitus. Owolabi LF et al70 
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did a case control study entitled “Electrodiagnostic evaluation of median 
nerve conduction in Type II diabetes mellitus patients that were 
asymptomatic for peripheral neuropathy”. The study evaluated median nerve 
conduction of type 2 DM patients who were asymptomatic for neuropathy 
and to compare their findings with age and sex-matched healthy individuals. 
On comparison of the various parameters, the median nerve distal latencies 
and F-responses were significantly higher in the study group while the 
median nerve conduction velocities and amplitudes were significantly lower 
in the study group. Thus, early screening for peripheral neuropathy in 
diabetes was further stressed in their study. 
 Pearson correlation analysis of HbA1c with nerve conduction values 
revealed that the latency of median (sensory) nerve in the first group 
had a positive correlation with significant ‘p’ value and the amplitude 
of the same nerve in second group had a negative correlation with 
significant ‘p’ value. 
 Pearson correlation analysis of HbA1c with nerve conduction 
parameters revealed that latency, F-wave latency, conduction velocity 
of median (motor)nerve in the second group had a significant 
correlation with insignificant ‘p’ value. However in the first group 
except for amplitude all other parameters had an insignificant 
correlation with HbA1c. Our study revealed that the newly diagnosed 
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type 2 DM group’s latency and amplitude had a significant correlation 
with HbA1c values. Whereas, in the second group latency and 
conduction velocity had a significant correlation with HbA1c values. 
 Rinku Garg et al71 in their study on sensory and motor conduction of 
median nerve in asymptomatic type 2 DM subjects had similar results like 
our study. 
 Pearson correlation analysis shown in Table-9 indicates that in both 
groups HbA1c had an appropriate correlation with BMI and serum 
magnesium. The second group who had type 2 DM for more than five 
years had a lower serum magnesium levels with increased HbA1c 
values and so they are scattered above and to the left in the scatter 
diagram. 
 In Table-10, latency of all nerves was negatively correlated with 
serum magnesium. The amplitude and conduction velocities of all 
nerves were positively correlated with serum magnesium. So, serum 
magnesium seems to be a very good indicator of the effect of diabetes 
mellitus on peripheral nerves. 
So, in our study magnesium had a significant correlation with the glycemic 
control and with the nerve conduction parameters of the nerves studied. S.S. 
Antin et al72 had proved magnesium as a cause relating to the complications 
occurring in type 2 DM. So, magnesium supplementation in type 2 DM as 
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studied by Lima JDL et al73 proved to be useful in preventing the diabetic 
complications and to keep the blood glucose levels in a check. 
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SUMMARY AND CONCLUSION 
The resistance to insulin-stimulated diabetes is a serious threat to population 
health.  
 This study has brought out the significance of nerve conduction 
abnormalities in early stages of the disease process. In this study, it 
was observed that the nerve conduction velocity progressively 
decreased and latency increased from the first group to second group 
as duration of diabetes increased. Moreover, it has demonstrated that 
there is significant impairment of nerve conduction parameters in type 
2 DM patients even without subjective features suggestive of 
peripheral neuropathy. These findings are in accordance with those of 
previous researchers. Therefore, there is a need for methods to identify 
the at-risk diabetic patients for neuropathy. Routine nerve conduction 
studies should be done in diabetics at least on yearly basis. 
 This study has given an important clinch about the correlation of 
serum magnesium with the glycemic status of the individual. So, 
though it has not been mandatory to do serum magnesium levels as a 
routine investigation in diabetes mellitus, it is sure an investigation to 
be done for patients with long-standing diabetes and poorly controlled 
diabetes mellitus. It is true to the fact that routine surveillance for 
hypomagnesemia is done and the condition be treated whenever 
situation occur. A magnesium rich diet consisting of whole grains, 
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legumes, fruits and vegetables such as spinach, dry apricots may be 
recommended. Further studies on the role of magnesium 
supplementation in type 2 DM in our population is recommended. 
 HbA1c mean values for the group with longer duration of type 2 DM 
was higher and it was more than the targeted value for patients on 
therapy. The poor glycemic control in the second group correlated 
appropriately with serum magnesium levels. Blood glucose levels 
begin to have an impact on morbidity and mortality of the subject even 
before the diagnostic threshold for diabetes is reached. So, 
information communication and education regarding the modifiable 
risk factors should be emphasized to the population to achieve the 
targeted glycemic control. 
 In our study, there was no correlation between serum calcium levels 
and glycemic status or nerve conduction parameters. However, the 
fact that increased calcium levels can decrease the expression of 
glucose transporter proteins and consequently, decrease glucose 
uptake resulting in chronic hyperglycemia should be remembered.  
The human and economic costs of this epidemic are enormous. The 
increasing prevalence of this disorder will inevitably result in increasing 
proportions of deaths.  A united, global initiative is required to address this 
diabetes epidemic. 
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FUTURE STUDY PLAN 
This study is of public health importance in identifying the earlier diagnosis 
of neuropathy in type 2 DM. The planned future studies are 
 A cohort study with the same parameters and do serum calcium 
estimation in high risk groups. 
 To categorize the population based on their glycemic control and do 
the correlation of nerve conduction parameters. 
 A longitudinal study on a population of type 2 DM by doing serum 
magnesium levels before and after magnesium supplementation. 
 Comparing autonomic function tests in newly diagnosed type 2 DM 
and DM with duration more than five years. 
 Correlation of clinical effects of type 2 DM with age, sex, duration 
and glycemic control of the patient. 
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4 F 47 59 1.53 25.21 7.2 9.3 2 2.37 37.2 56.43 2.94 6.07 59.34 22.45 3.05 12.21 52.37
5 F 42 53.2 1.49 23.96 6.4 9.2 2.3 2.14 39.12 54.56 2.15 5.9 58.75 23.56 2.39 9.85 51.44
6 F 40 68.5 1.5 30.44 6.5 8.1 2.3 2.1 35.23 56.78 2.88 6.1 59.47 23.14 3.1 10.21 52.35
7 F 42 70 1.58 28.04 6.1 8.5 2 2.14 33.12 55.67 3.8 4.89 57.27 24.12 3.7 12.32 51.97
8 F 45 71 1.54 29.94 6.8 9 1.9 2.47 31.28 54.32 3.12 5.05 58.1 22.1 3.17 9.43 49.55
9 F 47 69 1.57 27.99 7 8.6 1.8 2.65 30.43 54.97 3.97 5.48 58.48 22.58 3.98 10.25 49.65
10 F 49 55.3 1.49 24.9 7.6 8.8 2 2.73 33 54.67 2.94 5.39 58.23 22.64 3.1 10.67 49.43
11 F 41 67.3 1.5 29.91 5.7 8.4 2.5 1.98 33.4 56.55 2.58 5.88 58.45 22.98 2.66 9.57 52.38
12 F 40 68 1.54 28.67 5.7 8.3 2.4 2.1 36.78 57.25 2.64 6.34 62.36 22.5 2.85 9.45 53.1
13 F 48 72 1.52 31.16 6.8 8.9 2.2 2.2 35.23 58.68 1.97 6.9 63.45 22.68 2.62 9.21 53.27
14 F 39 65.7 1.51 28.81 5.8 9.2 2.3 2.13 34.54 57.86 2.14 5.98 60.48 23.14 2.88 9.34 52.75
15 F 46 67.8 1.48 30.95 6.3 10 2.1 2.34 34.21 56.43 2.65 5.5 57.78 23.67 2.85 9.12 51.34
16 F 41 61.5 1.58 24.64 6 8.6 2.4 2.28 35.65 53.2 2.32 5.71 57.8 22.56 2.98 10.2 47.21
17 F 40 60 1.42 29.76 6.7 8.2 2.5 2.25 36.75 57.86 2.1 6.82 61.5 23.18 2.57 9.27 53.25
18 F 44 73.5 1.55 30.6 7.9 8.1 1.5 2.23 31.32 58.34 1.8 7 63.24 22.9 2.78 9.05 54.32
19 F 40 51 1.5 22.67 5.1 8.5 2.8 2.07 38.43 56.21 2.32 5.47 58.35 23.54 2.67 8.95 50.43
20 F 48 71.5 1.45 34 7.1 8 1.9 2.25 31.2 58.43 2.12 5.95 59.14 23.25 3.1 9.65 53.65
21 F 45 64 1.49 28.83 6.5 9.3 2.3 2.21 34.5 57.23 2.56 5.38 58.4 22.88 2.98 10.34 51.35
22 F 47 60.4 1.47 27.95 6.2 9.4 2 2.38 32.13 52.12 2.95 5.19 57.16 23.15 3.24 11.25 47.49
23 F 46 53 1.48 24.2 5.9 9 2.9 2.11 31.74 54.67 3.25 5.12 57.88 23.18 3.28 10.76 50.56
24 F 44 61.2 1.51 26.84 5.1 8.7 2.3 1.96 37.16 58.55 2.68 6.1 60.5 22.15 3.12 9.85 52.36
25 F 43 67 1.52 28.99 6.3 8.2 2.1 2.37 33.82 57.97 2.26 6.27 60.38 22.34 2.88 8.85 53.12
26 M 40 70.3 1.53 30.03 7 9.8 2 2.68 30.25 56.7 2.56 5.38 59 23.1 3.09 10.33 50.64
27 M 49 64.6 1.58 25.87 5.4 10 2.5 2.14 36.75 58.43 2.65 5.87 59.38 22.9 2.97 12.34 52.43
28 M 48 59.3 1.53 25.33 5.8 9.5 2.4 2.33 35.61 54.43 2.61 5.75 58.18 23.17 2.91 10.33 49.49
29 M 38 62.4 1.46 29.27 6.8 9.8 2.6 2.45 33.45 56.61 2.13 6.45 62.85 22.05 3.12 9.62 50.25
Group I : Type 2  DM patients with duration less  than 1 year 
MEDIAN N. MOTORSr. 
Mg
Sr.     
Ca
HbA1cBMI
Ht                 
(mts)
Wt            
(kgs)
Age   
(yrs)
Sex
SL.          
No.
MEDIAN N. SENSORY SURAL N. SENSORY
LAT  ms AMP  µV CV m/s LAT msAMP mV CV m/s FW LAT LAT  msAMP  µV CV m/s
30 M 47 65.5 1.51 28.73 6.9 11 2.4 2.18 33.43 59.43 2.25 6.08 62.19 22.36 2.83 10.33 54.26
31 M 56 68.5 1.56 28.12 6.5 9.7 2.2 2.31 34.91 56.78 2.46 5.82 60.5 22.54 2.99 9.96 50.98
32 M 48 64 1.59 25.31 6.2 10 1.9 2.4 31.28 54.4 3.12 5.1 59.23 23.1 3.59 8.32 49.27
33 M 51 60 1.62 22.86 5.4 8.2 2.6 2.17 38.82 56.88 2.15 6.23 61.6 22.65 3.1 9.15 50.48
34 M 43 66.5 1.53 28.41 6.6 9.2 2.8 2.32 37.23 54.38 2.48 5.88 59.25 22.87 2.97 8.75 49.91
35 M 49 67.5 1.58 27.04 7.1 9.8 1.7 2.84 31.2 56.25 3.89 4.96 57 23.55 3.96 9.35 50.81
36 M 50 63.4 1.52 27.44 6.9 8.9 2.2 2.65 32.67 54.12 2.68 5.49 57.13 23.24 3.19 13.25 49.13
37 M 46 71.5 1.7 24.74 5.1 8.7 2.1 2.34 40.45 56.83 2.75 5.38 58.45 23.12 3.17 12.84 50.65
38 M 48 68.4 1.62 26.06 5.7 9.2 2.6 2.51 39.27 56.75 2.8 5.78 58.71 23.1 3.02 11.55 51.48
39 M 50 70 1.65 25.71 6.1 11 2.1 2.56 36.18 58.37 3.68 6.12 59.67 22.97 3.65 13.69 53.45
40 M 52 65.5 1.59 25.91 4.8 9 2.9 1.95 40.03 56.38 3.56 6.24 59.28 23.25 3.72 9.88 54.5
41 M 42 74.8 1.54 31.54 7.6 8.2 1.6 2.77 33.54 56.18 2.57 5.12 58.5 23.17 3.12 9.16 51.43
42 M 48 79.5 1.78 25.09 6.9 8.6 2.3 2.31 32.71 56.77 2.5 5.86 58.9 22.68 2.96 14.25 50.82
43 M 49 60.4 1.59 23.89 6 9.5 2 2.2 33.51 54.26 2.49 5.75 59.15 23.54 2.99 11.1 49.1
44 M 54 57.8 1.67 20.72 5.1 9.8 2.1 2.4 31.02 55.53 2.63 5.66 58.38 23.23 3.11 10.91 49.77
45 M 51 59.6 1.64 22.16 7.8 8.7 1.9 2.53 36.5 56.32 2.16 4.58 57.2 22.65 3.19 9.93 51.23
BMI- Body Mass Index
HbA1c- Glycosylated hemoglobin 
Sr.Ca - Serum Calcium in mg/dl
Sr. Mg- Serum Magnesium in mg/dl
LAT - Latency Measured in milliseconds
AMP- Amplitude  Measured in Millivolts for motor and in micro volts for  sensory nerves
CV- conduction Velocity Measured in meter per seconds
FW LAT- F wave Latency Measured in Milli Seconds
Group I : Type 2  DM patients with duration less  than 1 year 
MEDIAN N. MOTORWt               
(kgs)
Age   
(yrs)
Sex
SL.          
No.
Sr. 
Mg
Sr.     
Ca
HbA1cBMI
Ht               
(mts)
MEDIAN N. SENSORY SURAL N. SENSORY
LAT  msAMP  µV CV m/s LAT  ms AMP mV CV m/s FW LAT LAT  ms AMP  µV CV m/s
1 F 54 59 1.58 23.63 7.8 9.3 1.7 2.28 32.12 50.56 3.13 5.21 57.23 25.23 3.56 7.8 47.84
2 F 53 61 1.53 26.05 7.6 8.2 1.6 2.27 33.2 51.25 3.15 6.23 54.35 24.97 3.54 7.91 48.95
3 F 65 60 1.5 26.67 8 9 1.9 2.98 30.9 49.8 3.24 5.65 56.75 25.56 3.49 7.6 47.85
4 F 60 64 1.52 27.7 7.2 8.2 2 2.65 31.32 54.33 3.31 6.15 58.72 25.68 3.25 8.13 52.37
5 F 59 52 1.44 25.07 7.1 8 2.1 2.45 34.2 55.45 2.98 5.45 59.23 23.56 3.68 9.1 50.78
6 F 62 67 1.54 28.25 6.5 8.8 2 2.31 35.86 52.12 2.67 5.95 55.67 23.14 3.29 8.47 51.89
7 F 54 61 1.52 26.4 6.1 8.8 2.3 3.45 33.75 52.85 3.45 4.89 57.18 26.32 3.85 9.54 46.83
8 F 58 60 1.56 24.65 7 9.1 1.9 2.91 32.25 51.28 3.14 5.12 54.21 24.92 3.12 9.13 47.25
9 F 61 73 1.57 29.62 7.3 8.5 1.5 3.1 30.4 50.32 3.29 4.35 54.32 25.18 2.97 8.28 47.1
10 F 63 55.3 1.49 24.91 6.9 8.9 2.4 2.44 34.21 52.38 3.43 5.18 53.2 25.64 2.58 9.63 48.83
11 F 57 67.3 1.51 29.52 7.7 9 2.3 2.12 29.85 54.32 3.12 5.16 52.69 24.98 3.54 9.13 49.14
12 F 52 59 1.46 27.67 5.1 8.4 2.3 2.13 35.78 53.87 2.89 5.24 53.25 23.5 2.86 8.25 50.45
13 F 51 74 1.59 29.27 6.3 8.8 2.4 3.45 30.31 54.62 3.42 6.86 54.75 25.87 3.52 9.15 47.81
14 F 49 65.7 1.54 27.7 4.6 9.4 2.2 2.1 34.26 52.75 2.95 6.12 55.65 23.14 2.78 9.12 45.5
15 F 55 58.3 1.49 26.26 6.3 8.6 2.3 2.14 32.16 52.68 3.17 5.43 54.1 23.67 3.96 8.13 47.92
16 M 50 61.5 1.58 24.64 6.5 9.8 2.3 2.21 32.73 51.25 2.97 5.32 53.48 23 2.54 9.22 46.66
17 M 47 60 1.42 29.75 8.4 8.9 2.5 2.05 28.54 55.67 3.42 5.79 51.25 24.19 3.12 9.95 45.25
18 M 44 73.5 1.55 30.59 7.9 10.2 1.4 3.15 29.2 48.75 3.11 6.15 52.35 23.86 2.99 8.45 47.28
19 M 40 51 1.5 22.67 6.8 9 1.5 2.3 30.5 50.5 3.25 6.23 53.18 24.54 3.28 10.12 49.33
20 M 48 71.5 1.45 34 7.4 9.6 1.4 2.68 31.59 51.24 2.92 5.97 52.5 23.25 3.15 9.43 47.25
21 M 45 64 1.49 28.82 6.5 8.8 1.5 3.65 34.51 53.45 2.95 5.88 51.54 23.88 2.39 8.17 50.45
22 M 47 60.4 1.47 27.95 7.1 9.3 1.7 2.56 32.18 52.71 3.13 5.5 51.36 24.19 3.88 9.26 49.15
23 M 46 53 1.48 24.2 8.9 8.9 1.9 2.03 29.45 49.35 3.19 6.25 52.35 24.96 3.52 8.75 49.25
24 M 44 61.2 1.51 26.84 6.6 10.6 2 2.33 34.18 54.65 3.24 5.12 51.33 25.12 2.59 9.56 50.05
25 M 43 67 1.52 28.99 7.1 9.2 2.1 3.12 32.61 55.32 3.28 5.23 53.71 25.64 3.57 8.82 49.25
26 M 49 70.3 1.53 30.03 8.1 10.4 1.8 2.13 29.65 50.95 3.15 5.17 52.95 24.99 3.22 9.05 46.85
27 M 49 64.6 1.58 25.87 7 9.4 1.8 2.54 33.57 51.27 2.78 5.25 51.23 23.65 3.47 8.5 45.5
28 M 48 59.3 1.53 25.33 7.4 9 1.7 2.67 33.45 52.13 3.41 5.68 50.45 26.12 2.55 9.35 47.14
29 M 38 62.4 1.46 29.27 7.5 9.1 1.9 2.87 32.75 53.69 2.93 6.12 51.65 23.16 2.98 10.5 46.28
30 M 47 65.5 1.51 28.73 8 8.8 1.7 3.14 30.05 51.28 3.15 5.67 50.35 23.91 3.61 9.86 47.88
Group II : Type 2  DM Patients with duration more than 5 years 
MEDIAN N. MOTORSL.              
No.
Sex
Age                
(yrs)
Wt(kgs) Ht(mts) BMI HbA1c
Sr. 
Ca+
Sr. Mg+
